0001104659-16-136568.txt : 20160803 0001104659-16-136568.hdr.sgml : 20160803 20160803163124 ACCESSION NUMBER: 0001104659-16-136568 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160803 DATE AS OF CHANGE: 20160803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioTelemetry, Inc. CENTRAL INDEX KEY: 0001574774 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 462568498 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55039 FILM NUMBER: 161804301 BUSINESS ADDRESS: STREET 1: 227 WASHINGTON STREET #210 CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 610-729-7000 MAIL ADDRESS: STREET 1: 227 WASHINGTON STREET #210 CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 10-Q 1 a16-11630_110q.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-55039

BioTelemetry, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		46-2568498
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

1000 Cedar Hollow Road
Malvern, Pennsylvania		19355
(Address of Principal Executive Offices)		(Zip Code)

(610) 729-7000

(Registrant’s Telephone Number, including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer x

Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of July 26, 2016, 28,025,489 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

Table of Contents

BIOTELEMETRY, INC.

QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2016

TABLE OF CONTENTS

		Page No.
PART I.	FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (Unaudited)	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4.	Controls and Procedures	20

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	21

SIGNATURES		22

Table of Contents

Unless the context otherwise indicates or requires, the terms “we,” “our,” “us,” “BioTelemetry” and the “Company,” as used in this Form 10-Q, refer to BioTelemetry, Inc. and its directly and indirectly owned subsidiaries as a combined entity, except where otherwise stated or where it is clear through the context that the terms refer only to BioTelemetry, Inc. exclusive of its subsidiaries or a specific subsidiary of BioTelemetry, Inc.

FORWARD-LOOKING STATEMENTS

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects of our products and our confidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements we make regarding our ability to increase demand for our products and services, to leverage our Mobile Cardiac Outpatient TelemetryTM (“MCOTTM”) platform to expand into new markets, our market share, our expectations regarding revenue trends in our segments and the achievement of cost efficiencies through process improvement and gross margin improvements. Such forward looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things:

· our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business;

· our ability to obtain and maintain adequate protection of our intellectual property;

· the effectiveness of our cost savings initiatives;

· our ability to educate physicians and continue to obtain prescriptions for our products and services;

· changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services;

· our ability to attract and retain talented executive management and sales personnel;

· the commercialization of new products;

· our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities;

· changes in governmental regulations and legislation;

· acceptance of our new products and services;

· adverse regulatory action;

· interruptions or delays in the telecommunications systems that we use;

· our ability to successfully resolve outstanding legal proceedings; and

· the other factors that are described in Item 1A. “Risk Factors” of our latest Annual Report on Form 10-K.

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

BIOTELEMETRY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

	(Unaudited)
	June 30, 2016			December 31, 2015

ASSETS

Current assets:
Cash and cash equivalents	$	25,443		$	18,986
Accounts receivable, net of allowance for doubtful accounts of $12,497 and $11,185, at June 30, 2016 and December 31, 2015, respectively	15,325			15,179
Other accounts receivable, net of allowance for doubtful accounts of $291 and $416, at June 30, 2016 and December 31, 2015, respectively	13,094			8,997
Inventory	3,471			2,378
Prepaid expenses and other current assets	1,668			1,505
Total current assets	59,001			47,045
Property and equipment, net	26,282			25,554
Intangible assets, net	32,232			19,981
Goodwill	37,205			29,831
Other assets	1,470			1,732
Total assets	$	156,190		$	124,143

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	10,610		$	8,496
Accrued liabilities	12,755			11,230
Current portion of capital lease obligations	269			287
Current portion of long-term debt	1,317			1,250
Deferred revenue	3,609			2,625
Total current liabilities	28,560			23,888

Deferred tax liability	1,278			1,233
Long-term capital lease obligations	157			101
Long-term debt	36,014			21,944
Other liabilities	1,683			1,051
Total liabilities	67,692			48,217

Stockholders’ equity:
Common stock—$.001 par value as of June 30, 2016 and December 31, 2015; 200,000,000 shares authorized as of June 30, 2016 and December 31, 2015; 28,025,489 and 27,277,939 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	28			27
Paid-in capital	276,484			272,070
Accumulated other comprehensive loss	(160		)	(12		)
Accumulated deficit	(187,854		)	(196,159		)
Total stockholders’ equity	88,498			75,926
Total liabilities and stockholders’ equity	$	156,190		$	124,143

See accompanying notes.

Table of Contents

BIOTELEMETRY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except share and per share amounts)

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Revenues:
Healthcare	$	42,165		$	36,255		$	83,314		$	71,236
Research	7,896			5,441			13,289			10,869
Technology	2,619			3,116			4,717			6,142
Total revenues	52,680			44,812			101,320			88,247

Cost of revenues:
Healthcare	13,470			12,808			26,632			25,985
Research	4,447			3,233			7,702			6,186
Technology	1,842			2,038			3,438			4,120
Total cost of revenues	19,759			18,079			37,772			36,291

Gross profit	32,921			26,733			63,548			51,956

Operating expenses:
General and administrative	14,388			12,206			26,724			23,603
Sales and marketing	7,124			6,926			14,669			14,109
Bad debt expense	2,664			2,175			5,302			4,524
Research and development	1,965			1,631			3,751			3,596
Other charges	1,659			1,210			3,447			3,070
Total operating expenses	27,800			24,148			53,893			48,902

Income from operations	5,121			2,585			9,655			3,054
Interest and other loss, net	(633		)	(439		)	(1,056		)	(829		)

Income before income taxes	4,488			2,146			8,599			2,225
(Provision for) benefit from income taxes	(153		)	25			(294		)	(123		)

Net income	$	4,335		$	2,171		$	8,305		$	2,102
Other comprehensive income:
Foreign currency translation (loss) gain	(150		)	2			(148		)	(9		)
Comprehensive income	$	4,185		$	2,173		$	8,157		$	2,093

Net income per common share:
Basic	$	0.16		$	0.08		$	0.30		$	0.08
Diluted	$	0.14		$	0.08		$	0.28		$	0.07
Weighted average number of common shares outstanding:
Basic	27,960,776			27,071,839			27,665,800			27,003,273
Diluted	30,056,717			28,918,106			29,619,296			28,873,089

See accompanying notes.

Table of Contents

BIOTELEMETRY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Six Months Ended June 30,
	2016			2015
OPERATING ACTIVITIES
Net income	$	8,305		$	2,102
Adjustments to reconcile net income to net cash provided by operating activities:
Bad debt expense	5,302			4,524
Depreciation	5,257			4,074
Non-cash lease expense	27			18
Deferred income tax expense	45			123
Stock-based compensation	2,619			2,182
Amortization of intangibles	1,673			1,885
Accretion of discount on debt	109			99
Changes in operating assets and liabilities:
Accounts and other receivables	(5,866		)	(4,015		)
Inventory	(786		)	(640		)
Prepaid expenses and other assets	505			668
Accounts payable	1,789			(1,232		)
Accrued and other liabilities	(1,453		)	(399		)
Liability associated with the Civil Investigative Demand	—			(6,400		)
Net cash provided by operating activities	17,526			2,989

INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(17,970		)	—
Purchases of property and equipment and investment in internally developed software	(5,692		)	(6,669		)
Net cash used in investing activities	(23,662		)	(6,669		)

FINANCING ACTIVITIES
Payments related to the exercising of stock options and vesting of RSUs and PSUs	(1,089		)	(935		)
Borrowings under revolving loans	14,500			—
Principal payments on long-term debt	(635		)	(313		)
Principal payments on capital lease obligations	(183		)	(276		)
Net cash provided by (used in) financing activities	12,593			(1,524		)

Net increase (decrease) in cash and cash equivalents		6,457			(5,204	)
Cash and cash equivalents - beginning of period		18,986			20,007
Cash and cash equivalents - end of period	$	25,443		$	14,803

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	$	654		$	359
Cash paid for taxes	$	132		$	161

See accompanying notes.

Table of Contents

BIOTELEMETRY, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(In thousands, except share and per share amounts)

1. Summary of Significant Accounting Policies

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows. In the opinion of management, these consolidated financial statements reflect all adjustments which are of a normal recurring nature and necessary for a fair presentation of BioTelemetry, Inc.’s (“BioTelemetry,” “Company,” “we,” “our” or “us” ) financial position as of June 30, 2016 and December 31, 2015, the results of operations for the three months and six months ended June 30, 2016 and 2015 and cash flows for the six months ended June 30, 2016 and 2015. The financial data and other information disclosed in these notes to the consolidated financial statements related to the three and six months ended June 30, 2016 and 2015 are unaudited. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for any future period.

Net Income Per Share

We compute net income per share in accordance with Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by giving effect to all potential dilutive common shares, including stock options and restricted stock units.

The following table presents the calculation of basic net income per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
	(Net income in thousands)
Numerator:
Net income	$	4,335	$	2,171	$	8,305	$	2,102
Denominator:
Weighted average shares used in computing basic net income per share	27,960,776		27,071,839		27,665,800		27,003,273
Potential dilutive common shares due to dilutive stock option and restricted stock units	2,095,941		1,846,267		1,953,496		1,869,816
Weighted average shares used in computing diluted net income per share	30,056,717		28,918,106		29,619,296		28,873,089
Net income per share:
Basic net income per share	$	0.16	$	0.08	$	0.30	$	0.08
Diluted net income per share	$	0.14	$	0.08	$	0.28	$	0.07

Certain stock options, which are priced higher than the market price of our shares as of June 30, 2016 and 2015, would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income per share. These options could become dilutive in future periods.

Fair Value of Financial Instruments

The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. We have financial instruments falling into all three levels of the fair value hierarchy. Our Level 1 financial instruments consist primarily of cash and cash equivalents, accounts receivable, other accounts receivable and accounts payable. The carrying value of these financial instruments approximates their fair value because of their short-term nature. Long-term debt, which is given a Level 2 classification within the fair value hierarchy, was determined to have a fair value of $38,091 as of June 30, 2016. This is equal to the nominal value, which is the carrying value, exclusive of debt discount and deferred charges.

Table of Contents

The fair value of contingent consideration, which is a Level 3 fair value instrument, is measured on a recurring basis using unobservable inputs such as projected payment dates, probabilities of meeting specified milestones and other such variables resulting in payment amounts which are discounted back to present value using a probability-weighted discounted cash flow model.

In addition to our recurring fair value measurements, we have assets acquired in connection with business combinations, which are recorded at fair value on the acquisition date using a discounted cash flow model, which is a Level 3 classification. This valuation technique requires the Company to make certain assumptions, including, but not limited to, future operating performance and cash flows, royalty rates and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future operating cash flow of the acquired business, the characteristics of the assets acquired and liabilities assumed and the experience of the acquired business.

Equity Method Investments

We account for investments using the equity method of accounting if the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets as a component of other assets and is periodically adjusted for capital contributions, dividends received and our share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded as a component of interest and other loss, net in the consolidated statements of operations.

In December 2015, we acquired approximately 29% of the outstanding stock of Well Bridge Health, Inc. (“WellBridge”) through the conversion of an outstanding note receivable and the related accrued interest. The investment is accounted for under the equity method. At the time of the acquisition, the equity method basis difference of $891 was allocated to equity method goodwill. As of June 30, 2016, our investment in WellBridge amounted to $985. For the three and six months ended June 30, 2016, no capital contributions were made, nor were any dividends received. Our share of the investee’s loss for the three and six months ended June 30, 2016 was $93 and $114, respectively.

Goodwill and Acquired Intangible Assets

Goodwill is the excess of the purchase price of an acquired business over the amounts assigned to the assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles — Goodwill and Other (“ASC 350”), goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill. If the carrying value of the reporting units’ goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.

For the purpose of performing our goodwill impairment analysis, we consider our business to be comprised of three reporting units: Healthcare, Research and Technology. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units.

Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives of intangible assets are determined by assessing many factors including estimates of future operating performance and cash flow of the acquired business, the characteristics of the intangible assets acquired and the experience of the acquired business. Independent appraisal firms may assist with the valuation of acquired assets. The impairment test for indefinite-lived intangible assets other than goodwill consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset.

Recent Accounting Pronouncements Not Yet Adopted

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Account Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting. The standard will revise accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. The standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Table of Contents

In February 2016, the FASB issued ASU 2016-02, Leases. The standard will require lessees to recognize most leases on their balance sheet and makes selected changes to lessor accounting. The standard is effective for annual and interim reporting periods beginning after December 15, 2018. A modified retrospective transition approach is required, with certain practical expedients available. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. The standard will require inventory to be measured at the lower of cost or net realizable value. The guidance will not apply to inventories for which cost is determined using the last-in, first-out method or the retail inventory method. The standard is effective for annual and interim reporting periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which has been updated through several revisions and clarifications since its original issuance. The standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which a company expects to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition. The standard will be effective January 1, 2018 with early adoption permissible beginning January 1, 2017. We are currently evaluating the transition method we will elect and the impact the adoption of this standard will have on our consolidated financial statements.

2. Acquisitions

VirtualScopics, Inc.

On March 25, 2016, the Company, through its wholly-owned subsidiary BioTelemetry Research Acquisition Corporation, entered into a definitive Agreement and Plan of Merger with VirtualScopics, Inc. (“VirtualScopics”), a leading provider of clinical trial imaging solutions. Under the terms of the Merger Agreement, the Company commenced a Tender Offer to purchase: (i) any and all outstanding shares of VirtualScopics’ $0.001 par value common stock for $4.05 per share; (ii) any and all outstanding shares of VirtualScopics’ $0.001 par value Series A and Series B Convertible Preferred Stock for $336.30 per share; and (iii) any and all outstanding shares of VirtualScopics’ $0.001 par value Series C-1 Convertible Preferred Stock for $920.00 per share. The all cash Tender Offer commenced on April 8, 2016 and ended on May 9, 2016. The Company completed the acquisition of VirtualScopics on May 11, 2016. The total consideration paid at closing amounted to $14,970, net of cash acquired of $849.

The acquisition of VirtualScopics expands the Company’s existing clinical research offerings and gives the Company further access to established customer relationships. We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the consideration paid over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. The Company recognized $4,633 of goodwill as a result of the acquisition, all of which has been assigned to the Research segment. We do not expect that any of this goodwill will be deductible for tax purposes.

The amounts below represent our preliminary fair value estimates as of June 30, 2016 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period. The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets. The Company expects to finalize all accounting for the acquisition of VirtualScopics within one year of the acquisition date.

Table of Contents

The total consideration and related allocation for VirtualScopics is summarized as follows:

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Cash and cash equivalents	$	849
Other accounts receivable	3,679
Inventory	111
Prepaid expenses and other current assets	396
Property and equipment	524
Other assets	10

Identifiable intangible assets:
Customer relationships	5,100		12
Technology	1,900		10
Backlog	3,100		4
Total identifiable intangible assets	10,100
Total assets acquired	15,669

Fair value of liabilities assumed:
Accounts payable	325
Accrued liabilities	3,074
Current portion of capital lease obligations	59
Current portion of long-term debt	66
Deferred revenue	700
Long-term capital lease obligations	162
Long-term debt	97
Total liabilities assumed	4,483
Total identifiable net assets	11,186
Goodwill	4,633
Net assets acquired	$	15,819

For the period from May 11, 2016 to June 30, 2016, VirtualScopics contributed net revenues of $2,589 and net income of $166 to our consolidated results of operations.

The following unaudited pro forma financial information has been prepared using historical financial results of the Company and VirtualScopics as if the acquisition had occurred as of January 1, 2015. Certain adjustments related to the elimination of transaction costs and acquisition related indebtedness, as well as the addition of depreciation and amortization related to fair value adjustments on the tangible and identifiable intangible assets acquired, have been reflected for the purposes of the unaudited pro forma financial information presented below. No adjustments for synergies or certain other expected benefits of the acquisition have been included. We believe the assumptions used in preparing the unaudited pro forma financial information are reasonable, but not necessarily indicative of actual results should the acquisitions have occurred on January 1, 2015.

Pro forma financial information for the periods presented is summarized as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Revenue	$	54,762	$	47,832	$	107,258	$	94,081
Net income	$	5,021	$	1,847	$	9,643	$	1,541
Net income per common share:
Basic	$	0.18	$	0.07	$	0.35	$	0.06
Diluted	$	0.17	$	0.06	$	0.33	$	0.05
Weighted average number of common shares outstanding:
Basic	27,960,776		27,071,839		27,665,800		27,003,273
Diluted	30,056,717		28,918,106		29,619,296		28,873,089

Table of Contents

ePatch Division of DELTA Danish Electronics, Light, and Acoustics

On April 1, 2016, the Company, through its wholly-owned subsidiary BioTelemetry Technology ApS, entered into an Asset Purchase Agreement (“APA”) with DELTA Danish Electronics, Light, and Acoustics (“DELTA”), pursuant to which the Company acquired substantially all of the assets of the ePatch division of DELTA, inclusive of all products and indications currently under development. The total consideration paid at closing amounted to $3,000 in cash and 244,519 shares of the Company’s common stock valued at $2,885. In addition, there is the potential for a performance based earn out up to $3,000 upon reaching certain milestones, as defined in the APA. The fair value of the total consideration transferred in the ePatch acquisition, including contingent consideration, was $6,490 at the acquisition date.

The ePatch acquisition is expected to generate future cost savings for the Company and will provide control over proprietary components for the Company’s next generation Mobile Cardiac Outpatient TelemetryTM (“MCOTTM”) device. We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the consideration paid over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. The company recognized $2,808 of goodwill as a result of the acquisition, all of which has been assigned to the Technology segment. The total amount of goodwill preliminarily expected to be deductible for tax purposes is $2,808.

The amounts below represent our preliminary fair value estimates as of June 30, 2016 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period. The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets. The Company expects to finalize all accounting for the ePatch acquisition within one year of the acquisition date.

The total consideration and related allocation for the ePatch acquisition is summarized as follows:

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Inventory	$	200
Property and equipment	175

Identifiable intangible assets:
Customer relationships	400		10
Technology	3,000		10
Trade names	100		Indefinite
Total identifiable intangible assets	3,500
Total assets acquired	3,875

Fair value of liabilities assumed:
Accrued liabilities	193
Total liabilities assumed	193
Total identifiable net assets	3,682
Goodwill	2,808
Net assets acquired	$	6,490

While the ePatch acquisition provides control over proprietary components of our next generation cardiac monitoring device, the acquisition did not have a material effect on our consolidated results of operations.

Contingent Consideration

The APA includes the potential for a performance based earn out up to $3,000 upon reaching certain milestones. The fair value of the contingent consideration associated with the ePatch acquisition was $605 at June 30, 2016 and is included as a component of other liabilities in the accompanying consolidated balance sheets.

Table of Contents

The following summarizes the changes in our contingent consideration during the six months ended June 30, 2016:

	Total Contingent Consideration
Balance at December 31, 2015	—
Purchase price contingent consideration	$	605
Balance at June 30, 2016	$	605

3. Inventory

Inventory consists of the following:

	June 30, 2016		December 31, 2015
Raw materials	$	2,850	$	2,115
Finished goods	621		263
Total inventory	$	3,471	$	2,378

Inventory, which includes purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.

4. Intangible Assets and Goodwill

Goodwill was recognized at the time of our acquisitions. The carrying amount of goodwill as of June 30, 2016 and December 31, 2015 was $37,205 and $29,831, respectively. The increase in goodwill during the three and six months ended June 30, 2016 relates to the Company’s recent acquisitions of VirtualScopics and the ePatch division of DELTA.

The changes in the carrying amounts of goodwill by segment were as follows:

	Reporting Segment
	Healthcare		Research		Technology			Total
Balance at December 31, 2015	$	14,724	$	11,950	$	3,157		$	29,831
Goodwill acquired during the year	—		4,633		2,808			7,441
Impact of foreign exchange	—		—		(67		)	(67		)
Balance at June 30, 2016	$	14,724	$	16,583	$	5,898		$	37,205

The gross carrying amounts and accumulated amortization of our intangible assets as of June 30, 2016 and December 31, 2015 are as follows:

	Estimated Useful Life (Years)	June 30, 2016			December 31, 2015
Customer relationships	5 - 15	$	16,191		$	10,700
Technology, including internally developed software	3 - 10	18,757			13,522
Signed backlog	1 - 4	6,260			3,160
Unsigned backlog	4	600			600
Covenants not to compete	5 - 7	1,040			1,040
Total intangible assets, gross		42,848			29,022
Customer relationships accumulated amortization		(3,083		)	(2,520		)
Technology accumulated amortization		(5,918		)	(5,422		)
Signed backlog accumulated amortization		(3,051		)	(2,609		)
Unsigned backlog accumulated amortization		(575		)	(500		)
Covenants not to compete accumulated amortization		(587		)	(490		)
Total accumulated amortization		(13,214		)	(11,541		)
Indefinite-lived trade names		2,598			2,500
Total intangible assets, net		$	32,232		$	19,981

Table of Contents

The estimated amortization expense for the next five years and thereafter is summarized as follows at June 30, 2016:

Remainder of 2016	$	2,125
2017	4,805
2018	4,319
2019	3,832
2020	3,282
2021	2,764
Thereafter	8,507
Total estimated amortization	$	29,634

Amortization expense for the three months ended June 30, 2016 and 2015 was $994 and $985, respectively, and amortization expense for the six months ended June 30, 2016 and 2015 was $1,673 and $1,885, respectively.

5. Credit Agreement

On December 30, 2014, we entered into a Credit Agreement with Healthcare Financial Solutions, LLC (“HFS”), previously The General Electric Capital Corporation, as agent for the lenders (“Lenders”), and as a lender and swingline lender. Pursuant to the Credit Agreement, the Lenders agreed to make loans to us as follows: (i) Term Loans in an amount of $25,000 as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed $10,000 and (ii) Revolving Loans up to $15,000. As of June 30, 2016, $14,500 was drawn on the Revolving Loans. The loan, inclusive of Term Loans and Revolving Loans, is recorded on our consolidated balance sheets as of June 30, 2016 in the amount of $37,178, which is net of a debt discount of $695 related to fees paid to HFS and deferred charges of $65.

The loan bears interest at an annual rate of LIBOR plus 4.0%, subject to a LIBOR floor of 1.0%. The outstanding principal of the Term Loan will be paid as follows: (i) beginning April 1, 2015, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $312, plus accrued interest; (ii) beginning January 1, 2018, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $625, plus accrued interest; and (iii) the remaining $16,563 will be paid in full on or before December 30, 2019, or such earlier date upon an acceleration of the Term Loan by the Lenders upon an event of default or termination by us. The loan is secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries, as well as a pledge of 65% of the capital stock of the Company’s foreign subsidiaries.

The Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of June 30, 2016, we were in compliance with all covenants.

6. Stockholders’ Equity

Stock-Based Compensation

Stock options, restricted stock units (“RSUs”), performance stock units (“PSUs”) and performance stock options (“PSOs”) are granted under the BioTelemetry, Inc. 2008 Equity Incentive Plan (“EIP”). In January 2016, the number of shares available for grant was increased by 1,091,118 shares, per the EIP documents. At June 30, 2016, approximately 2,746,978 shares remain available for grant under the EIP. We recognized $1,441 and $1,062 of stock-based compensation expense for the three months ended June 30, 2016 and 2015, respectively. We recognized $2,619 and $2,182 of stock-based compensation expense for the six months ended June 30, 2016 and 2015, respectively.

Table of Contents

Stock option, RSU and PSU activity is summarized as follows:

	Stock Options				Restricted Stock Units				Performance Stock Units
	Number of Shares		Weighted Average Exercise Price		Number of Shares		Weighted Average Grant Date Fair Value		Number of Shares		Weighted Average Grant Date Fair Value
Stock outstanding as of December 31, 2015	3,420,519		$	6.69	690,936		$	6.85	265,990		$	8.68
Granted	282,270		9.67		177,212		9.87		—		—
Cancelled/forfeited	(19,422	)	8.38		(7,405	)	9.57		—		—
Exercised/vested	(125,650	)	3.37		(271,793	)	2.87		—		—
Stock outstanding as of March 31, 2016	3,557,717		$	7.04	588,950		$	9.57	265,990		$	8.68
Granted	100,000		16.61		47,986		15.44		—		—
Cancelled/forfeited	(7,600	)	9.78		—		—		—		—
Exercised/vested	(57,019	)	4.94		(16,240	)	8.01		(132,998	)	8.68
Stock outstanding as of June 30, 2016	3,593,098		$	7.33	620,696		$	10.06	132,992		$	8.68

Stock-based compensation expense is only recognized for outstanding PSUs where the performance conditions are deemed probable for achievement. For PSUs deemed probable for achievement, stock-based compensation expense is recognized ratably over the expected vesting period. For the three and six months ended June 30, 2016 we incurred PSU expenses of $355 and $444, respectively. No stock-based compensation expense was recorded on our PSUs for the three and six months ended June 30, 2015. As of June 30, 2016 the Company has not deemed it probable that the outstanding PSUs will vest.

In 2015, 200,000 PSOs were granted. There were no forfeitures or vesting of PSOs during the three or six months ended June 30, 2016. Stock-based compensation expense will only be recognized once the performance conditions of the outstanding PSOs have been met. Through June 30, 2016, no stock-based compensation expense has been recognized related to the PSOs.

Employee Stock Purchase Plan

In the six months ended June 30, 2016, 77,844 shares were purchased in accordance with the Employee Stock Purchase Plan (“ESPP”). Net proceeds from the issuance of shares of common stock under the ESPP for the six months ended June 30, 2016 were $531. In January 2016, the number of shares available for grant was increased by 272,779 shares, per the ESPP documents. At June 30, 2016, approximately 698,220 shares remain available for purchase under the ESPP.

7. Other Charges

We account for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and record the expenses in other charges in our consolidated statements of operations and record the related accrual in the accrued liabilities line on our consolidated balance sheets. These costs are primarily disclosed as severance and employee related costs below.

We account for expenses associated with integration and certain litigation as other charges as incurred. These expenses were primarily a result of legal fees related to patent litigation and activities surrounding our acquisitions. A summary of these expenses is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Legal fees	$	1,242	$	1,171	$	2,611	$	2,799
Professional fees	278		12		446		24
Severance and employee related costs	72		27		323		247
Other costs	67		—		67		—
Total	$	1,659	$	1,210	$	3,447	$	3,070

8. Income Taxes

The income tax provision for interim periods is determined using an estimated annual effective tax rate adjusted for discrete items, if any, which are taken into account in the quarterly period in which they occur. We review and update our estimated annual effective tax rate each quarter. At June 30, 2016, our estimated annual effective tax rate was 3.81%. Income tax expense of $294 was recorded for the six months ended June 30, 2016, primarily due to Alternative Minimum Tax (“AMT”) levied on current year taxable income, net of allowable AMT net operating loss carryovers. At June 30, 2015, our estimated annual effective tax rate was 6.42%. We recorded a tax provision of $123 for the six months ended June 30, 2015, which includes a discrete charge of $117 related to a deferred tax liability recorded for indefinite-lived intangibles.

Table of Contents

As of June 30, 2016, in accordance with ASC 740, Income Taxes, we maintained a full valuation allowance against net deferred tax assets, with the exception of the deferred tax liability recorded for indefinite lived intangibles. We will continue to maintain a full valuation allowance until such time we can reasonably estimate the probability of realizing a benefit from the deferred tax assets.

9. Segment Information

We operate under three segments: Healthcare, Research and Technology. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders with our comprehensive suite of cardiac monitoring solutions in a healthcare setting. Our Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. Intercompany revenues relating to the manufacturing of devices by the Technology segment for the other segments is included on the intersegment revenues line.

Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses, including research and development costs incurred by the Technology segment for the benefit of the other segments, as well as the elimination of costs associated with intercompany revenues are included in Corporate and Other. Also included in Corporate and Other is our net interest expense and other financing expenses as well as the loss from equity method investments. We do not allocate assets to the individual segments.

For the three months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
*June 30, 2016*
Revenues	$	42,165	$	7,896	$	2,619	—			$	52,680
Intersegment revenues	—		—		2,282		$	(2,282	)	—
Income (loss) before income taxes	15,582		387		747		(12,228		)	4,488
Depreciation and amortization	2,500		1,080		142		(58		)	3,664
Capital expenditures	1,626		541		12		—			2,179

	Healthcare		Research			Technology		Corporate and Other			Consolidated
*June 30, 2015*
Revenues	$	36,255	$	5,441		$	3,116	—			$	44,812
Intersegment revenues	4		—			3,023		$	(3,027	)	—
Income (loss) before income taxes	10,990		(175		)	1,359		(10,028		)	2,146
Depreciation and amortization	1,853		933			91		130			3,007
Capital expenditures	3,182		1,413			2		—			4,597

For the six months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
*June 30, 2016*
Revenues	$	83,314	$	13,289	$	4,717	—			$	101,320
Intersegment revenues	—		—		5,674		$	(5,674	)	—
Income (loss) before income taxes	29,782		405		1,693		(23,281		)	8,599
Depreciation and amortization	4,981		1,884		192		(127		)	6,930
Capital expenditures	4,316		1,350		26		—			5,692

	Healthcare		Research		Technology		Corporate and Other			Consolidated
*June 30, 2015*
Revenues	$	71,236	$	10,869	$	6,142	—			$	88,247
Intersegment revenues	4		—		4,014		$	(4,018	)	—
Income (loss) before income taxes	19,879		202		2,272		(20,128		)	2,225
Depreciation and amortization	3,662		1,841		185		271			5,959
Capital expenditures	4,330		2,269		70		—			6,669

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2015, and in conjunction with the accompanying quarterly unaudited condensed consolidated financial statements. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those contained in these forward-looking statements due to a number of factors, including, but not limited to, those set forth herein and elsewhere in this report and in our other filings with the U.S. Securities and Exchange Commission (“SEC”). See the “Forward-Looking Statements” section at the beginning of this report.

Company Background

We provide cardiac monitoring services, cardiac monitoring device manufacturing and centralized core laboratory services. We operate under three reportable segments: Healthcare, Research and Technology. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. We offer cardiologists and electrophysiologists with a full spectrum of solutions which provides them with a single source of cardiac monitoring services. These services range from the differentiated Mobile Cardiac Telemetry (“MCT”) service marketed as Mobile Cardiac Outpatient TelemetryTM (“MCOTTM”) or External Cardiac Ambulatory Telemetry (“ECAT”), to wireless and trans-telephonic event, Holter, Pacemaker and International Normalized Ratio (“INR”) monitoring. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for pharmaceutical and medical device clinical trials. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals.

Recent Acquisitions

On March 25, 2016, the Company entered into a definitive Agreement and Plan of Merger with VirtualScopics, Inc. (“VirtualScopics”), a leading provider of clinical trial imaging solutions. Under the terms of the Merger Agreement, the Company commenced a Tender Offer to purchase any and all outstanding shares of VirtualScopics’ common stock and preferred stock. The all cash Tender Offer commenced on April 8, 2016 and ended on May 9, 2016, pursuant to which the business and operations of VirtualScopics were acquired by the Company. The total consideration paid at closing amounted to $15.0 million, net of cash acquired of $0.8 million.

On April 1, 2016, the Company entered into an Asset Purchase Agreement with DELTA Danish Electronics, Light, and Acoustics (“DELTA”), pursuant to which the Company acquired substantially all of the assets of the ePatch division of DELTA, inclusive of all products and indications currently under development. The total consideration paid at closing amounted to $3.0 million in cash and 244,519 shares of the Company’s common stock valued at $2.9 million. In addition, there is the potential for a performance based earn out up to $3.0 million upon reaching certain milestones, as defined in the APA. The fair value of the total consideration transferred in the acquisition, including contingent consideration, was $6.5 million at the acquisition date.

Revenue Recognition

Healthcare

Healthcare revenue includes revenue from MCT, wireless and trans telephonic event, Holter, Pacemaker and INR monitoring services. We receive a significant portion of our revenue from third-party commercial insurance organizations and governmental entities. We also receive reimbursement directly from patients through co-pays and self-pay arrangements. Billings for services reimbursed by contracted third-party payors, including Medicare, are recorded as revenue, net of contractual allowances. Adjustments to the estimated receipts, based on final settlement with the third-party payors, are recorded upon settlement. If we do not have sufficient historical information regarding collectability from a given payor to support revenue recognition at the time of service, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until the service has been completed. For the three months ended June 30, 2016 and 2015, revenue from Medicare as a percentage of our Healthcare revenue was 41.4% and 40.7%, respectively. For the six months ended June 30, 2016 and 2015, revenue from Medicare as a percentage of our Healthcare revenue was 41.6% and 41.0%, respectively.

Table of Contents

Research

Research revenue includes revenue for core laboratory services, including cardiac monitoring, imaging, scientific consulting and data management services. Our Research revenue is provided on a fee-for-service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and this revenue is recognized as the services are performed. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed.

For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management’s best estimate of their selling prices, when vendor-specific or third-party evidence is unavailable.

We record reimbursements received for out-of-pocket expenses incurred, including freight, as revenue in the accompanying consolidated statements of operations.

Technology

Technology revenue includes revenue received from the sale of products, product repairs and supplies to medical companies, clinics and hospitals. Our Technology revenue is recognized when shipped, or as service is completed.

Reimbursement - Healthcare

We are dependent on reimbursement for our patient services by government and commercial insurance payors. Medicare reimbursement rates for our MCT, event, Holter, Pacemaker and INR monitoring services have been established nationally by the Centers for Medicare and Medicaid Services (“CMS”) and fluctuate periodically based on the annually published CMS rate table.

In addition to government reimbursement through Medicare, we have successfully secured contracts with most national and regional commercial payors for our monitoring services.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable related to the Healthcare segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the consolidated balance sheets net of an allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record an allowance for doubtful accounts based on the aging of receivables using company-specific historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections and the aging of receivables by payor. Because of continuing changes in the healthcare industry and third-party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows.

Other accounts receivable related to the Research and Technology segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate the allowance for doubtful accounts on a specific account basis and consider several factors in our analysis, including customer-specific information and the aging of the account.

We write-off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Healthcare segment, we wrote off $3.9 million and $3.1 million of receivables for the six months ended June 30, 2016 and 2015, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write-offs in the Research and Technology segments. We recorded bad debt expense of $2.7 million and $5.3 million, respectively, for the three and six months ended June 30, 2016. We recorded bad debt expense of $2.2 million and $4.5 million, respectively, for the three and six months ended June 30, 2015.

Other Charges

Other charges are related to litigation, strategic acquisitions, cost reduction programs and reorganizations, as well as other costs that are not considered part of our ongoing business operations.

Table of Contents

Results of Operations

Three Months Ended June 30, 2016 and 2015

Revenues. Total revenues for the three months ended June 30, 2016 were $52.7 million compared to $44.8 million for the three months ended June 30, 2015, reflecting an increase of $7.9 million, or 17.6%. Healthcare revenue increased $5.9 million due to increased patient volumes as well as higher MCT Medicare pricing. Research revenue increased $2.5 million, primarily due to the acquisition of VirtualScopics during the quarter. Technology revenue decreased $0.5 million due to lower sales volume resulting from customers delaying purchases as they await the release of upgraded devices.

Gross Profit. Gross profit increased to $32.9 million for the three months ended June 30, 2016 from $26.7 million for the three months ended June 30, 2015, reflecting an increase of $6.2 million, or 23.1%. Gross profit as a percentage of revenues was 62.5% for the three months ended June 30, 2016 compared to 59.7% for the three months ended June, 2015. The increase in gross margin percentage was due to volume efficiencies, higher MCT Medicare pricing as well as reduced costs related to shipping and device monitoring. These increases were partially offset by the impact of our acquisitions, which carry lower profit margins than our existing business.

General and Administrative Expense. General and administrative expense was $14.4 million for the three months ended June 30, 2016 compared to $12.2 million for the three months ended June 30, 2015. The increase of $2.2 million, or 17.9%, was due to the addition of $1.0 million for our acquired businesses as well as a $1.0 million increase in employee related expense and a $0.4 million increase in stock-based compensation. These increases were partially offset by a $0.2 million decrease in amortization as intangible assets have become fully amortized. As a percent of total revenues, general and administrative expense was 27.3% for the three months ended June 30, 2016 compared to 27.2% for the three months ended June 30, 2015.

Sales and Marketing Expense. Sales and marketing expense was $7.1 million for the three months ended June 30, 2016 compared to $6.9 million for the three months ended June 30, 2015. The increase of $0.2 million, or 2.9%, was due to the addition of $0.3 million for our acquired businesses, partially offset by a $0.1 million decrease in employee related costs. As a percent of total revenues, sales and marketing expense was 13.5% for the three months ended June 30, 2016 compared to 15.5% for the three months ended June 30, 2015.

Bad Debt Expense. Bad debt expense was $2.7 million for the three months ended June 30, 2016 compared to $2.2 million for the three months ended June 30, 2015. The increase of $0.5 million, or 22.5%, was due to the timing of revenues and collections. As a percentage of total revenues, bad debt expense was 5.1% for the three months ended June 30, 2016 compared to 4.9% for the three months ended June 30, 2015. Substantially all of our bad debt expense relates to the Healthcare segment. Bad debt expense in the Research and Technology segments, which include our recently acquired companies, was minimal and is recorded on a specific account basis.

Research and Development Expense. Research and development expense was $2.0 million for the three months ended June 30, 2016 compared to $1.6 million for the three months ended June 30, 2015. The increase of $0.4 million, or 20.5%, was due to the addition of $0.3 million for our acquired businesses and a $0.1 million increase in consulting costs. As a percent of total revenues, research and development expense was 3.7% for the three months ended June 30, 2016 compared to 3.6% for the three months ended June 30, 2015.

Other Charges. During the three months ended June 30, 2016, we incurred $1.7 million of other charges primarily related to legal fees for patent litigation as well as professional services related to our second quarter acquisitions. For the three months ended June 30, 2016, other charges were 3.1% of total revenues.

During the three months ended June 30, 2015, we incurred $1.2 million of other charges. Legal expense of $1.2 million was primarily related to patent litigation. For the three months ended June 30, 2015, other charges were 2.7% of total revenues.

Interest and Other Loss, net. Interest and other loss, net was $0.6 million for the three months ended June 30, 2016 compared to $0.4 million for the three months ended June 30, 2015. The increase was due to our share of our equity method investee’s loss as well as an increase in interest expense due to increased borrowings under the Revolving Loans.

Income Taxes. At June 30, 2016, our estimated annual effective tax rate was a provision of 3.81% and we had income tax expense of $0.2 million for the three months ended June 30, 2016. At June 30, 2015, our estimated annual effective tax rate was a provision of 6.42% and a slight income tax benefit was recorded for the three months ended June 30, 2015.

Table of Contents

Net Income. We recognized net income of $4.3 million for the three months ended June 30, 2016 compared to a net income of $2.2 million for the three months ended June 30, 2015.

Six Months Ended June, 2016 and 2015

Revenues. Total revenues for the six months ended June 30, 2016 were $101.3 million compared to $88.2 million for the six months ended June 30, 2015, representing an increase of $13.1 million, or 14.8%. Healthcare revenue increased $12.1 million due to increased patient volumes as well as higher MCT Medicare pricing. Research revenue increased $2.4 million, primarily due to the acquisition of VirtualScopics. Technology revenue decreased $1.4 million due to lower sales volume resulting from customers delaying purchases as they await the release of upgraded devices.

Gross Profit. Gross profit increased to $63.5 million for the six months ended June 30, 2016 from $52.0 million for the six months ended June 30, 2015, representing an increase of $11.5 million, or 22.3%. Gross profit as a percentage of revenues was 62.7% for the six months ended June 30, 2016 compared to 58.9% for the six months ended June, 2015. The increase in gross margin percentage was due to volume efficiencies, reduced costs related to shipping and device monitoring as well as higher MCT Medicare pricing. These increases were slightly offset by the impact of our acquisitions, which carry lower profit margins than our existing business.

General and Administrative Expense. General and administrative expense was $26.7 million for the six months ended June 30, 2016 compared to $23.6 million for the six months ended June 30, 2015. The increase of $3.1 million, or 13.2%, was due to the addition of $1.0 million for our acquired businesses as well as a $1.7 million increase in employee related expenses and a $0.4 million increase in stock-based compensation. As a percent of total revenues, general and administrative expense was 26.4% for the six months ended June 30, 2016 compared to 26.7% for the six months ended June 30, 2015.

Sales and Marketing Expense. Sales and marketing expense was $14.7 million for the six months ended June 30, 2016 compared to $14.1 million for the six months ended June 30, 2015. The increase of $0.6 million, or 4.0%, was due to the addition of $0.3 million for our acquired businesses, a $0.2 million increase in meeting and travel related costs and a $0.1 million increase in consulting costs. As a percent of total revenues, sales and marketing expense was 14.5% for the six months ended June 30, 2016 compared to 16.0% for the six months ended June 30, 2015.

Bad Debt Expense. Bad debt expense was $5.3 million for the six months ended June 30, 2016 compared to $4.5 million for the six months ended June 30, 2015. The increase of $0.8 million, or 17.2%, was due to the timing of revenues and collections. As a percentage of total revenues, bad debt expense was 5.2% for the six months ended June 30, 2016 compared to 5.1% for the six months ended June 30, 2015. Substantially all of our bad debt expense relates to the Healthcare segment. Bad debt expense in the Research and Technology segments, which include our recently acquired companies, was minimal and is recorded on a specific account basis.

Research and Development Expense. Research and development expense was $3.8 million for the six months ended June 30, 2016 compared to $3.6 million for the six months ended June 30, 2015. The increase of $0.2 million, or 4.3%, due to the addition of $0.3 million for our acquired businesses, partially offset by a $0.1 million decrease in consulting costs. As a percent of total revenues, research and development expense was 3.7% for the six months ended June 30, 2016 compared to 4.1% for the six months ended June 30, 2015.

Other Charges. During the six months ended June 30, 2016, we incurred $3.4 million of other charges primarily related to legal fees for patent litigation as well as professional services related to our second quarter acquisitions. For the six months ended June 30, 2016, other charges were 3.4% of total revenues.

During the six months ended June 30, 2015, we incurred $3.1 million of other charges. Legal charges of $2.8 million were primarily related to patent litigation. The severance and employee related costs of $0.2 million were associated with integration activities surrounding our 2014 acquisitions. For the six months ended June 30, 2015, other charges were 3.5% of total revenues.

Interest and Other Loss, net. Interest and other loss, net was $1.1 million for the six months ended June 30, 2016 compared to $0.8 million for the six months ended June 30, 2015. The increase was due to our share of our equity method investee’s loss as well as an increase in interest expense due to increased borrowings under the Revolving Loans.

Income Taxes. At June 30, 2016, our estimated annual effective tax rate was a provision of 3.81% and we had income tax expense of $0.3 million for the six months ended June 30, 2016. At June 30, 2015, our estimated annual effective tax rate was a provision of 6.42% and $0.1 million of income tax benefit was recorded for the six months ended June 30, 2015.

Table of Contents

Net Income. We recognized net income of $8.3 million for the six months ended June 30, 2016 compared to a net income of $2.1 million for the six months ended June 30, 2015.

Liquidity and Capital Resources

Our Annual Report on Form 10-K for the year ended December 31, 2015 includes a detailed discussion of our liquidity, contractual obligations and commitments. The information presented below updates and should be read in conjunction with the information disclosed in that Form 10-K.

As of June 30, 2016, our principal source of liquidity was cash and cash equivalents of $25.4 million and net accounts and other receivables of $28.4 million. We had working capital of $30.4 million as of June 30, 2016.

We generated $17.5 million of cash from operations for the six months ended June 30, 2016. Our ongoing operations during this period resulted in net income of $8.3 million, which included $15.0 million of non-cash items primarily related to bad debt, depreciation, amortization and stock-based compensation expense. These items were partially offset by $5.8 million of cash used for working capital.

We used $23.7 million of cash in investing activities for the six months ended June 30, 2016. We used $15.0 million, net of cash acquired, in the acquisition of VirtualScopics and $3.0 million in the acquisition of the ePatch Division of DELTA. In addition, we used $5.7 million of cash for capital purchases primarily related to medical devices in the Healthcare and Research segments for use in our ongoing operations and an investment in internally developed software for the six months ended June 30, 2016.

In December 2014, we entered into a $25.0 million Term Loan and $15.0 Revolving Loans with Healthcare Financial Solutions, LLC, previously The General Electric Capital Corporation. During the six months ended June 30, 2016, we borrowed $14.5 million under the revolving loan.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our cash balance as of June 30, 2016 was $25.4 million. We do not invest in any trading securities, nor do we use derivative financial instruments.

At June 30, 2016, we had $37.9 million of variable rate debt, exclusive of debt discounts and deferred charges, based off of LIBOR rates. A change in LIBOR rates would result in an incremental change in interest expense.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in Company reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Exchange Act as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2016 to ensure that information required to be disclosed in these reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the six months ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, in the ordinary course of business, and like others in the industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority or are involved in traditional employment or business litigation. We review such requests and notices and take appropriate action.

The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be projected.

Item 1A. Risk Factors

In evaluating an investment in BioTelemetry common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2015, as well as the information contained in this Quarterly Report and other reports and registration statements filed by us with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit Number

31.1		Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as amended.
31.2		Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as amended.
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Label Linkbase Document
101.PRE		XBRL Taxonomy Presentation Linkbase Document
101.DEF		XBRL Taxonomy Definition Linkbase Document

Table of Contents

BioTelemetry, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOTELEMETRY, INC.


Date: August 3, 2016	By:	/s/ Heather C. Getz
		Heather C. Getz, CPA
		Senior Vice President and Chief Financial Officer
		(Principal Financial Officer and authorized officer of the Registrant)

EX-31.1 2 a16-11630_1ex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION

I, Joseph H. Capper, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTelemetry, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2016


/s/ Joseph H. Capper
Joseph H. Capper
President and Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 a16-11630_1ex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION

I, Heather C. Getz, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioTelemetry, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2016


/s/ Heather C. Getz
Heather C. Getz, CPA
Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 a16-11630_1ex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Joseph H. Capper, the President and Chief Executive Officer of BioTelemetry, Inc. (the “Company”), and Heather C. Getz, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2016


/s/ Joseph H. Capper		/s/ Heather C. Getz
Joseph H. Capper		Heather C. Getz, CPA
President and Chief Executive Officer		Senior Vice President and Chief Financial Officer

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 beat-20160630.xml XBRL INSTANCE DOCUMENT 0001574774 us-gaap:EmployeeStockMember 2016-04-01 2016-06-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2016-06-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2016-03-31 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2015-12-31 0001574774 beat:PerformanceStockOptionMember 2015-01-01 2015-12-31 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2016-04-01 2016-06-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2016-01-01 2016-03-31 0001574774 us-gaap:EmployeeStockMember 2016-06-30 0001574774 beat:EquityIncentivePlan2008Member 2016-06-30 0001574774 us-gaap:EmployeeStockMember 2016-01-01 2016-01-31 0001574774 us-gaap:PerformanceSharesMember 2016-04-01 2016-06-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2016-06-30 0001574774 us-gaap:PerformanceSharesMember 2016-06-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2016-03-31 0001574774 us-gaap:PerformanceSharesMember 2016-03-31 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001574774 us-gaap:PerformanceSharesMember 2015-12-31 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2016-04-01 2016-06-30 0001574774 beat:PerformanceStockOptionMember 2016-04-01 2016-06-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember 2016-01-01 2016-06-30 0001574774 us-gaap:EmployeeStockMember 2016-01-01 2016-06-30 0001574774 beat:ResearchServicesMember 2016-04-01 2016-06-30 0001574774 beat:ProductSegmentMember 2016-04-01 2016-06-30 0001574774 beat:PatientServiceSegmentMember 2016-04-01 2016-06-30 0001574774 beat:ResearchServicesMember 2016-01-01 2016-06-30 0001574774 beat:PatientServiceSegmentMember 2016-01-01 2016-06-30 0001574774 beat:ResearchServicesMember 2015-04-01 2015-06-30 0001574774 beat:ProductSegmentMember 2015-04-01 2015-06-30 0001574774 beat:PatientServiceSegmentMember 2015-04-01 2015-06-30 0001574774 beat:ResearchServicesMember 2015-01-01 2015-06-30 0001574774 beat:ProductSegmentMember 2015-01-01 2015-06-30 0001574774 beat:PatientServiceSegmentMember 2015-01-01 2015-06-30 0001574774 beat:VirtualscopicsMember 2016-05-11 2016-06-30 0001574774 us-gaap:RevolvingCreditFacilityMember beat:HealthcareFinancialSolutionsLlcHsfMember 2014-12-30 0001574774 us-gaap:RevolvingCreditFacilityMember beat:HealthcareFinancialSolutionsLlcHsfMember 2016-06-30 0001574774 us-gaap:TradeNamesMember 2016-06-30 0001574774 us-gaap:TradeNamesMember 2015-12-31 0001574774 beat:MednetEntitiesMember 2015-01-01 2015-06-30 0001574774 beat:ProductSegmentMember 2016-01-01 2016-06-30 0001574774 beat:VirtualscopicsMember beat:ResearchServicesMember 2016-01-01 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember beat:ProductSegmentMember 2016-01-01 2016-06-30 0001574774 beat:ResearchServicesMember 2016-06-30 0001574774 beat:ProductSegmentMember 2016-06-30 0001574774 beat:PatientServiceSegmentMember 2016-06-30 0001574774 beat:ResearchServicesMember 2015-12-31 0001574774 beat:ProductSegmentMember 2015-12-31 0001574774 beat:PatientServiceSegmentMember 2015-12-31 0001574774 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001574774 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001574774 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001574774 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001574774 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001574774 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001574774 beat:SignedBacklogMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0001574774 beat:SignedBacklogMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0001574774 beat:UnsignedBacklogMember 2016-01-01 2016-06-30 0001574774 us-gaap:NoncompeteAgreementsMember 2016-06-30 0001574774 us-gaap:DevelopedTechnologyRightsMember 2016-06-30 0001574774 us-gaap:CustomerRelationshipsMember 2016-06-30 0001574774 beat:UnsignedBacklogMember 2016-06-30 0001574774 beat:SignedBacklogMember 2016-06-30 0001574774 us-gaap:NoncompeteAgreementsMember 2015-12-31 0001574774 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0001574774 us-gaap:CustomerRelationshipsMember 2015-12-31 0001574774 beat:UnsignedBacklogMember 2015-12-31 0001574774 beat:SignedBacklogMember 2015-12-31 0001574774 us-gaap:OtherAssetsMember beat:WellBridgeHealthIncMember 2016-06-30 0001574774 us-gaap:GoodwillMember beat:WellBridgeHealthIncMember 2015-12-31 0001574774 beat:WellBridgeHealthIncMember 2015-12-31 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2016-04-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ProductSegmentMember 2016-04-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2016-04-01 2016-06-30 0001574774 beat:CorporateAndReconcilingItemsMember 2016-04-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2016-01-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ProductSegmentMember 2016-01-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2016-01-01 2016-06-30 0001574774 beat:CorporateAndReconcilingItemsMember 2016-01-01 2016-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2015-04-01 2015-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ProductSegmentMember 2015-04-01 2015-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2015-04-01 2015-06-30 0001574774 beat:CorporateAndReconcilingItemsMember 2015-04-01 2015-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2015-01-01 2015-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:ProductSegmentMember 2015-01-01 2015-06-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2015-01-01 2015-06-30 0001574774 beat:CorporateAndReconcilingItemsMember 2015-01-01 2015-06-30 0001574774 beat:TermLoanAndRevolvingLoanMember beat:HealthcareFinancialSolutionsLlcHsfMember 2016-06-30 0001574774 us-gaap:SecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember beat:GeCapitalMember 2014-12-30 2014-12-30 0001574774 us-gaap:SecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember beat:GeCapitalMember 2014-12-30 2014-12-30 0001574774 us-gaap:SecuredDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember beat:GeCapitalMember 2014-12-30 2014-12-30 0001574774 2015-06-30 0001574774 2014-12-31 0001574774 beat:VirtualscopicsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-06-30 0001574774 beat:VirtualscopicsMember us-gaap:CustomerRelationshipsMember 2016-06-30 0001574774 beat:VirtualscopicsMember beat:BacklogMember 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember us-gaap:TradeNamesMember 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember us-gaap:CustomerRelationshipsMember 2016-06-30 0001574774 us-gaap:OtherLiabilitiesMember beat:EpatchDivisionOfDeltaDanishElectronicsMember 2016-06-30 0001574774 beat:VirtualscopicsMember us-gaap:CommonStockMember 2016-05-11 0001574774 beat:VirtualscopicsMember beat:SeriesC1ConvertiblePreferredStockMember 2016-05-11 0001574774 beat:VirtualscopicsMember beat:SeriesaAndBConvertiblePreferredStockMember 2016-05-11 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember 2016-04-01 0001574774 us-gaap:PerformanceSharesMember 2016-01-01 2016-06-30 0001574774 beat:PerformanceStockOptionMember 2016-01-01 2016-06-30 0001574774 us-gaap:PerformanceSharesMember 2016-01-01 2016-03-31 0001574774 us-gaap:PerformanceSharesMember 2015-04-01 2015-06-30 0001574774 us-gaap:PerformanceSharesMember 2015-01-01 2015-06-30 0001574774 beat:VirtualscopicsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-06-30 2016-06-30 0001574774 beat:VirtualscopicsMember us-gaap:CustomerRelationshipsMember 2016-06-30 2016-06-30 0001574774 beat:VirtualscopicsMember beat:BacklogMember 2016-06-30 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-06-30 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember us-gaap:CustomerRelationshipsMember 2016-06-30 2016-06-30 0001574774 2016-06-30 0001574774 2015-12-31 0001574774 2016-07-26 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember beat:EquityIncentivePlan2008Member 2016-01-01 2016-01-31 0001574774 us-gaap:SecuredDebtMember beat:HealthcareFinancialSolutionsLlcHsfMember 2014-12-30 0001574774 beat:VirtualscopicsMember 2016-05-11 2016-05-11 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember 2016-04-01 2016-04-01 0001574774 2016-04-01 2016-06-30 0001574774 2015-04-01 2015-06-30 0001574774 beat:GeCapitalMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-01-01 2016-06-30 0001574774 beat:GeCapitalMember 2016-01-01 2016-06-30 0001574774 beat:WellBridgeHealthIncMember 2016-04-01 2016-06-30 0001574774 beat:WellBridgeHealthIncMember 2016-01-01 2016-06-30 0001574774 beat:EpatchDivisionOfDeltaDanishElectronicsMember 2016-06-30 0001574774 beat:VirtualscopicsMember 2016-06-30 0001574774 beat:VirtualscopicsMember 2016-04-01 2016-06-30 0001574774 beat:VirtualscopicsMember 2016-01-01 2016-06-30 0001574774 beat:VirtualscopicsMember 2015-04-01 2015-06-30 0001574774 beat:VirtualscopicsMember 2015-01-01 2015-06-30 0001574774 2016-01-01 2016-06-30 0001574774 2015-01-01 2015-06-30 beat:segment beat:item iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD 99000 109000 27003273 27071839 27665800 27960776 28873089 28918106 29619296 30056717 605000 59000 193000 3074000 0 0 0.65 0.010 0.0642 0.0381 P1Y P1Y -6400000 10000000 67000 67000 -935000 -1089000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;"> <tr> <td valign="bottom" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Useful Life (Years) </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 5 - 15 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,191 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,700 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Technology, including internally developed software </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;"> 3 - 10 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,757 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,522 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Signed backlog </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 1 - 4 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,260 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,160 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Unsigned backlog </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;"> 4 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>600 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>600 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Covenants not to compete </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 5 - 7 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,040 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,040 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total intangible assets, gross </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,848 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,022 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Customer relationships accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,083 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,520 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Technology accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,918 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,422 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Signed backlog accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,051 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,609 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Unsigned backlog accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(575 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(500 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Covenants not to compete accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(587 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(490 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,214 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,541 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Indefinite-lived trade names </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,598 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total intangible assets, net </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,232 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,981 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> 1091118 false --12-31 Q2 2016 2016-06-30 10-Q 0001574774 28025489 Yes Accelerated Filer BioTelemetry, Inc.

8496000

10610000

15179000

15325000

11230000

12755000

-12000

-160000

P10Y

P4Y

P12Y

P10Y

272070000

276484000

2182000

1062000

355000

2619000

444000

1441000

11185000

12497000

416000

291000

1885000

985000

1673000

994000

124143000

156190000

47045000

59001000

2885000

244519

0.06

0.07

0.35

0.18

0.05

0.06

0.33

0.17

2808000

336.30

920.00

4.05

1541000

1847000

9643000

5021000

94081000

47832000

107258000

54762000

6490000

3000000

605000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 2. Acquisitions   VirtualScopics, Inc.   On March 25, 2016, the Company, through its wholly-owned subsidiary BioTelemetry Research Acquisition Corporation, entered into a definitive Agreement and Plan of Merger with VirtualScopics, Inc. (“VirtualScopics”), a leading provider of clinical trial imaging solutions.  Under the terms of the Merger Agreement, the Company commenced a Tender Offer to purchase:  (i) any and all outstanding shares of VirtualScopics’ $0.001 par value common stock for $4.05 per share; (ii) any and all outstanding shares of VirtualScopics’ $0.001 par value Series A and Series B Convertible Preferred Stock for $336.30 per share; and (iii) any and all outstanding shares of VirtualScopics’ $0.001 par value Series C-1 Convertible Preferred Stock for $920.00 per share.  The all cash Tender Offer commenced on April 8, 2016 and ended on May 9, 2016.  The Company completed the acquisition of VirtualScopics on May 11, 2016.  The total consideration paid at closing amounted to $14,970, net of cash acquired of $849.   The acquisition of VirtualScopics expands the Company’s existing clinical research offerings and gives the Company further access to established customer relationships.  We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values.  The excess of the consideration paid over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities.  The Company recognized $4,633 of goodwill as a result of the acquisition, all of which has been assigned to the Research segment.  We do not expect that any of this goodwill will be deductible for tax purposes.   The amounts below represent our preliminary fair value estimates as of June 30, 2016 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period.  The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets.  The Company expects to finalize all accounting for the acquisition of VirtualScopics within one year of the acquisition date.   The total consideration and related allocation for VirtualScopics is summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> Average Life </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amount </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Fair value of assets acquired: </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>849  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Other accounts receivable </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,679  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Inventory </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other current assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>396  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>524  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Other assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Identifiable intangible assets: </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,100  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> 12 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Technology </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,900  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> 10 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Backlog </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,100  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> 4 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Total identifiable intangible assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,100  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Total assets acquired </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,669  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Fair value of liabilities assumed: </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>325  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> Accrued liabilities </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,074  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Current portion of capital lease obligations </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> Current portion of long-term debt </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>700  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> Long-term capital lease obligations </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>162  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Long-term debt </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> Total liabilities assumed </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,483  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Total identifiable net assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,186  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,633  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Net assets acquired </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,819  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   For the period from May 11, 2016 to June 30, 2016, VirtualScopics contributed net revenues of $2,589 and net income of $166 to our consolidated results of operations.   The following unaudited pro forma financial information has been prepared using historical financial results of the Company and VirtualScopics as if the acquisition had occurred as of January 1, 2015.  Certain adjustments related to the elimination of transaction costs and acquisition related indebtedness, as well as the addition of depreciation and amortization related to fair value adjustments on the tangible and identifiable intangible assets acquired, have been reflected for the purposes of the unaudited pro forma financial information presented below.  No adjustments for synergies or certain other expected benefits of the acquisition have been included.  We believe the assumptions used in preparing the unaudited pro forma financial information are reasonable, but not necessarily indicative of actual results should the acquisitions have occurred on January 1, 2015.   Pro forma financial information for the periods presented is summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 85.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:40.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30, </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30, </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:40.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;"> Revenue </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,762  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,832  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107,258  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94,081  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;"> Net income </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,021  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,847  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,643  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,541  </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;"> Net income per common share: </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;"> Basic </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.18  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.07  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.35  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.06  </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;"> Diluted </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.17  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.06  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.05  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;"> Weighted average number of common shares outstanding: </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;"> Basic </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,960,776  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,071,839  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,665,800  </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,003,273  </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;"> Diluted </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,056,717  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,918,106  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,619,296  </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,873,089  </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.26%;padding:0pt;">   </td> <td valign="bottom" style="width:02.90%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.92%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;padding:0pt;">   </td> </tr> </table></div>   ePatch Division of DELTA Danish Electronics, Light, and Acoustics   On April 1, 2016, the Company, through its wholly-owned subsidiary BioTelemetry Technology ApS, entered into an Asset Purchase Agreement (“APA”) with DELTA Danish Electronics, Light, and Acoustics (“DELTA”), pursuant to which the Company acquired substantially all of the assets of the ePatch division of DELTA, inclusive of all products and indications currently under development.  The total consideration paid at closing amounted to $3,000 in cash and 244,519 shares of the Company’s common stock valued at $2,885.  In addition, there is the potential for a performance based earn out up to $3,000 upon reaching certain milestones, as defined in the APA.  The fair value of the total consideration transferred in the ePatch acquisition, including contingent consideration, was $6,490 at the acquisition date.   The ePatch acquisition is expected to generate future cost savings for the Company and will provide control over proprietary components for the Company’s next generation Mobile Cardiac Outpatient TelemetryTM (“MCOTTM”) device.  We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values.  The excess of the consideration paid over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities.  The company recognized $2,808 of goodwill as a result of the acquisition, all of which has been assigned to the Technology segment.  The total amount of goodwill preliminarily expected to be deductible for tax purposes is $2,808.   The amounts below represent our preliminary fair value estimates as of June 30, 2016 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period.  The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets.  The Company expects to finalize all accounting for the ePatch acquisition within one year of the acquisition date.   The total consideration and related allocation for the ePatch acquisition is summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #FFFFFF;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.20%;background-color: #FFFFFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #FFFFFF;padding:0pt;"> Average Life </td> <td valign="bottom" style="width:01.20%;background-color: #FFFFFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amount </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Fair value of assets acquired: </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Inventory </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>200  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>175  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Identifiable intangible assets: </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>400  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> 10 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Technology </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,000  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> 10 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Trade names </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> Indefinite </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Total identifiable intangible assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,500  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Total assets acquired </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,875  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Fair value of liabilities assumed: </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Accrued liabilities </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>193  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Total liabilities assumed </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>193  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Total identifiable net assets </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,682  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,808  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Net assets acquired </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,490  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   While the ePatch acquisition provides control over proprietary components of our next generation cardiac monitoring device, the acquisition did not have a material effect on our consolidated results of operations.   Contingent Consideration   The APA includes the potential for a performance based earn out up to $3,000 upon reaching certain milestones.  The fair value of the contingent consideration associated with the ePatch acquisition was $605 at June 30, 2016 and is included as a component of other liabilities in the accompanying consolidated balance sheets.   The following summarizes the changes in our contingent consideration during the six months ended June 30, 2016:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:63.84%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:31.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total Contingent Consideration </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:63.84%;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2015 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:31.36%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:63.84%;padding:0pt;"> Purchase price contingent consideration </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:29.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>605  </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:63.84%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:29.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:63.84%;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2016 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:29.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>605  </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:63.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:29.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

3875000

15669000

162000

849000

10000

396000

3679000

325000

700000

66000

3500000

10100000

400000

3000000

100000

3100000

5100000

1900000

200000

111000

193000

4483000

3682000

11186000

97000

175000

524000

6490000

15819000

287000

269000

101000

157000

20007000

14803000

18986000

25443000

0.001

200000000

27277939

28025489

27277939

28025489

27000

28000

2093000

2173000

8157000

4185000

36291000

18079000

37772000

19759000

6186000

3233000

7702000

4447000

0.040

312000

16563000

625000

695000

123000

45000

65000

2625000

3609000

1233000

1278000

4074000

5257000

5959000

271000

3662000

185000

1841000

3007000

130000

1853000

91000

933000

6930000

-127000

4981000

192000

1884000

3664000

-58000

2500000

142000

1080000

0.08

0.30

0.16

0.07

0.08

0.28

0.14

0.29

891000

985000

11541000

2609000

500000

2520000

5422000

490000

13214000

3051000

575000

3083000

5918000

587000

8507000

4805000

2125000

2764000

3282000

3832000

4319000

29022000

3160000

600000

10700000

13522000

1040000

42848000

6260000

600000

16191000

18757000

1040000

29634000

P4Y

P1Y

P15Y

P5Y

P10Y

P3Y

P7Y

P5Y

23603000

12206000

26724000

14388000

29831000

14724000

3157000

11950000

37205000

2808000

14724000

5898000

16583000

4633000

7441000

2808000

4633000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   4.Intangible Assets and Goodwill   Goodwill was recognized at the time of our acquisitions. The carrying amount of goodwill as of June 30, 2016 and December 31, 2015 was $37,205 and $29,831, respectively. The increase in goodwill during the three and six months ended June 30, 2016 relates to the Company’s recent acquisitions of VirtualScopics and the ePatch division of DELTA.   The changes in the carrying amounts of goodwill by segment were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:38.64%;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:57.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Reporting Segment </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.64%;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.64%;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2015 </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,724 </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,950 </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,157 </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,831 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.64%;padding:0pt;"> Goodwill acquired during the year </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,633 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,808 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,441 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.64%;background-color: #CCEEFF;padding:0pt;"> Impact of foreign exchange </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67 </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.28%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:38.64%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.64%;padding:0pt;"> Balance at June 30, 2016 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,724 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,583 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,898 </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,205 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.64%;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> </table></div>   The gross carrying amounts and accumulated amortization of our intangible assets as of June 30, 2016 and December 31, 2015 are as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;"> <tr> <td valign="bottom" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Useful Life (Years) </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Customer relationships </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 5 - 15 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,191 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,700 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Technology, including internally developed software </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;"> 3 - 10 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,757 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,522 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Signed backlog </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 1 - 4 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,260 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,160 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Unsigned backlog </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;"> 4 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>600 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>600 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Covenants not to compete </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;"> 5 - 7 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,040 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,040 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total intangible assets, gross </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,848 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,022 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Customer relationships accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,083 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,520 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Technology accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,918 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,422 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Signed backlog accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,051 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,609 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Unsigned backlog accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(575 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(500 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Covenants not to compete accumulated amortization </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(587 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(490 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total accumulated amortization </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,214 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,541 </td> <td valign="bottom" style="width:01.06%;"> ) </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;"> Indefinite-lived trade names </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,598 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500 </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;"> Total intangible assets, net </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,232 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,981 </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:52.32%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;padding:0pt;">   </td> </tr> </table></div>   The estimated amortization expense for the next five years and thereafter is summarized as follows at June 30, 2016:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"> Remainder of 2016 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,125  </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,805  </td> <td valign="bottom" style="width:01.16%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,319  </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,832  </td> <td valign="bottom" style="width:01.16%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,282  </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,764  </td> <td valign="bottom" style="width:01.16%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,507  </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;padding:0pt;"> Total estimated amortization </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.54%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,634  </td> <td valign="bottom" style="width:01.16%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:82.12%;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;">   </td> </tr> </table></div>   Amortization expense for the three months ended June 30, 2016 and 2015 was $994 and $985, respectively, and amortization expense for the six months ended June 30, 2016 and 2015 was $1,673 and $1,885, respectively. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

-67000

51956000

26733000

63548000

32921000

25985000

12808000

26632000

13470000

71236000

36255000

83314000

42165000

2225000

-20128000

19879000

2272000

202000

2146000

-10028000

10990000

1359000

-175000

8599000

-23281000

29782000

1693000

405000

4488000

-12228000

15582000

747000

387000

114000

93000

161000

132000

123000

-123000

-25000

294000

153000

4015000

5866000

-1232000

1789000

-399000

-1453000

640000

786000

-668000

-505000

1869816

1846267

1953496

2095941

2500000

2598000

19981000

32232000

359000

654000

263000

621000

2378000

3471000

2115000

2850000

2799000

1171000

2611000

1242000

48217000

67692000

124143000

156190000

23888000

28560000

14500000

15000000

25000000

37178000

1250000

1317000

38091000

21944000

36014000

-5204000

6457000

-1524000

12593000

-6669000

-23662000

2989000

17526000

2102000

2171000

8305000

4335000

166000

-829000

-439000

-1056000

-633000

48902000

24148000

53893000

27800000

3054000

2585000

9655000

5121000

1732000

1470000

-9000

2000

-148000

-150000

3070000

1210000

3447000

1659000

1051000

1683000

8997000

13094000

3000000

17970000

14970000

6669000

4330000

70000

2269000

4597000

3182000

2000

1413000

5692000

4316000

26000

1350000

2179000

1626000

12000

541000

6669000

5692000

0.001

1505000

1668000

531000

14500000

24000

12000

446000

278000

25554000

26282000

4524000

2175000

5302000

2664000

276000

183000

313000

635000

3596000

1631000

3751000

1965000

-196159000

-187854000

88247000

-4018000

71236000

6142000

10869000

4000

4014000

44812000

-3027000

36255000

3116000

5441000

4000

3023000

101320000

-5674000

83314000

4717000

13289000

5674000

52680000

-2282000

42165000

2619000

7896000

2282000

2589000

10869000

5441000

13289000

7896000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   For the three months ended:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,165 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,896 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,619 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,680 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,282 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,282 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,582 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>387 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>747 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,228 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,488 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,080 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>142 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,664 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,626 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>541 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,179 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,255 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,441 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,116 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,812 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,023 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,027 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,990 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(175 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,359 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,028 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,146 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,853 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>933 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,007 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,182 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,413 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,597 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   For the six months ended:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,314 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,289 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,717 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,320 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,674 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,674 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,782 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>405 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,693 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,281 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,599 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,981 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,884 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(127 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,930 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,316 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,350 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,692 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,236 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,869 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,142 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88,247 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,018 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,879 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,272 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20,128 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,225 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,662 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,841 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,959 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,330 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,269 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,669 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   9.Segment Information   We operate under three segments:  Healthcare, Research and Technology.  The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders with our comprehensive suite of cardiac monitoring solutions in a healthcare setting.  Our Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals.  Intercompany revenues relating to the manufacturing of devices by the Technology segment for the other segments is included on the intersegment revenues line.   Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income.  Any remaining expenses, including research and development costs incurred by the Technology segment for the benefit of the other segments, as well as the elimination of costs associated with intercompany revenues are included in Corporate and Other.  Also included in Corporate and Other is our net interest expense and other financing expenses as well as the loss from equity method investments.  We do not allocate assets to the individual segments.   For the three months ended:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,165 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,896 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,619 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,680 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,282 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,282 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,582 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>387 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>747 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,228 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,488 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,080 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>142 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,664 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,626 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>541 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,179 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,255 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,441 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,116 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,812 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,023 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,027 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,990 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(175 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,359 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,028 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,146 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,853 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>933 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,007 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,182 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,413 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,597 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   For the six months ended:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2016 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,314 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,289 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,717 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,320 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,674 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,674 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,782 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>405 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,693 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,281 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,599 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,981 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,884 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(127 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,930 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,316 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,350 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,692 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Healthcare </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Technology </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate and Other </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consolidated </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Revenues </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,236 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,869 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,142 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88,247 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Intersegment revenues </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,018 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Income (loss) before income taxes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,879 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,272 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20,128 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,225 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,662 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,841 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,959 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> Capital expenditures </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,330 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,269 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,669 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

14109000

6926000

14669000

7124000

247000

27000

323000

72000

2182000

2619000

7405

9.57

177212

47986

9.87

15.44

265990

690936

265990

588950

132992

620696

8.68

6.85

8.68

9.57

8.68

10.06

271793

132998

16240

2.87

8.68

8.01

272779

2746978

698220

19422

7600

200000

282270

100000

3420519

3557717

3593098

6.69

7.04

7.33

77844

3.37

4.94

8.38

9.78

9.67

16.61

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   1.Summary of Significant Accounting Policies   The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X.  Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows.  In the opinion of management, these consolidated financial statements reflect all adjustments which are of a normal recurring nature and necessary for a fair presentation of BioTelemetry, Inc.’s (“BioTelemetry,” “Company,” “we,” “our” or “us” ) financial position as of June 30, 2016 and December 31, 2015, the results of operations for the three months and six months ended June 30, 2016 and 2015 and cash flows for the six months ended June 30, 2016 and 2015.  The financial data and other information disclosed in these notes to the consolidated financial statements related to the three and six months ended June 30, 2016 and 2015 are unaudited.  The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for any future period.   Net Income Per Share   We compute net income per share in accordance with Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period.  Diluted net income per share is computed by giving effect to all potential dilutive common shares, including stock options and restricted stock units.   The following table presents the calculation of basic net income per share:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30, </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30, </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:50.90%;padding:0pt;"> (Net income in thousands) </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Numerator: </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Net income </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,335  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,171  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,305  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,102  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Denominator: </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Weighted average shares used in computing basic net income per share </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,960,776  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,071,839  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,665,800  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,003,273  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Potential dilutive common shares due to dilutive stock option and restricted stock units </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,095,941  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,846,267  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,953,496  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,869,816  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Weighted average shares used in computing diluted net income per share </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,056,717  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,918,106  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,619,296  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,873,089  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Net income per share: </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Basic net income per share </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.16  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.08  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.30  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.08  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Diluted net income per share </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.14  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.08  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.28  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.07  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Certain stock options, which are priced higher than the market price of our shares as of June 30, 2016 and 2015, would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income per share. These options could become dilutive in future periods.   Fair Value of Financial Instruments   The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties.  We have financial instruments falling into all three levels of the fair value hierarchy.  Our Level 1 financial instruments consist primarily of cash and cash equivalents, accounts receivable, other accounts receivable and accounts payable.  The carrying value of these financial instruments approximates their fair value because of their short-term nature.  Long-term debt, which is given a Level 2 classification within the fair value hierarchy, was determined to have a fair value of $38,091 as of June 30, 2016. This is equal to the nominal value, which is the carrying value, exclusive of debt discount and deferred charges.   The fair value of contingent consideration, which is a Level 3 fair value instrument, is measured on a recurring basis using unobservable inputs such as projected payment dates, probabilities of meeting specified milestones and other such variables resulting in payment amounts which are discounted back to present value using a probability-weighted discounted cash flow model.   In addition to our recurring fair value measurements, we have assets acquired in connection with business combinations, which are recorded at fair value on the acquisition date using a discounted cash flow model, which is a Level 3 classification.  This valuation technique requires the Company to make certain assumptions, including, but not limited to, future operating performance and cash flows, royalty rates and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future operating cash flow of the acquired business, the characteristics of the assets acquired and liabilities assumed and the experience of the acquired business.   Equity Method Investments   We account for investments using the equity method of accounting if the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company’s ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets as a component of other assets and is periodically adjusted for capital contributions, dividends received and our share of the investee’s earnings or losses together with other-than-temporary impairments which are recorded as a component of interest and other loss, net in the consolidated statements of operations.   In December 2015, we acquired approximately 29% of the outstanding stock of Well Bridge Health, Inc. (“WellBridge”) through the conversion of an outstanding note receivable and the related accrued interest.  The investment is accounted for under the equity method.  At the time of the acquisition, the equity method basis difference of $891 was allocated to equity method goodwill.  As of June 30, 2016, our investment in WellBridge amounted to $985.  For the three and six months ended June 30, 2016, no capital contributions were made, nor were any dividends received.  Our share of the investee’s loss for the three and six months ended June 30, 2016 was $93 and $114, respectively.   Goodwill and Acquired Intangible Assets   Goodwill is the excess of the purchase price of an acquired business over the amounts assigned to the assets acquired and liabilities assumed in a business combination.  In accordance with ASC 350, Intangibles — Goodwill and Other (“ASC 350”), goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists.  The provisions of ASC 350 require that we perform a two-step impairment test.  In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units.  If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill.  If the carrying value of the reporting units’ goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.   For the purpose of performing our goodwill impairment analysis, we consider our business to be comprised of three reporting units:  Healthcare, Research and Technology.  We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches.  The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment.  The market approach utilizes our market data.  There are inherent uncertainties related to these factors and the judgment applied in the analysis.  We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units.   Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives of intangible assets are determined by assessing many factors including estimates of future operating performance and cash flow of the acquired business, the characteristics of the intangible assets acquired and the experience of the acquired business. Independent appraisal firms may assist with the valuation of acquired assets. The impairment test for indefinite-lived intangible assets other than goodwill consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset.   Recent Accounting Pronouncements Not Yet Adopted   In March 2016, the Financial Accounting Standards Board (“FASB”) issued Account Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting.  The standard will revise accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows.  The standard is effective for annual and interim periods beginning after December 15, 2016.  Early adoption is permitted.  We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases.  The standard will require lessees to recognize most leases on their balance sheet and makes selected changes to lessor accounting.  The standard is effective for annual and interim reporting periods beginning after December 15, 2018.  A modified retrospective transition approach is required, with certain practical expedients available.  We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.   In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory.  The standard will require inventory to be measured at the lower of cost or net realizable value.  The guidance will not apply to inventories for which cost is determined using the last-in, first-out method or the retail inventory method.  The standard is effective for annual and interim reporting periods beginning after December 15, 2016.  Early adoption is permitted.  We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.   In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which has been updated through several revisions and clarifications since its original issuance.  The standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which a company expects to receive in exchange for those goods or services.  The standard also requires new, expanded disclosures regarding revenue recognition.  The standard will be effective January 1, 2018 with early adoption permissible beginning January 1, 2017.  We are currently evaluating the transition method we will elect and the impact the adoption of this standard will have on our consolidated financial statements. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

117000

75926000

88498000

125650

57019

-18000

-27000

4120000

2038000

3438000

1842000

6142000

3116000

4717000

2619000

28873089

28918106

29619296

30056717

27003273

27071839

27665800

27960776

EX-101.SCH 6 beat-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Summary of Significant Accounting Policies - Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Acquisitions - VirtualScopics, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Intangible Assets and Goodwill - Gross Carrying Amounts and Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Other Charges (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Credit Agreement link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Other Charges link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Other Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Acquisitions - Pro Forma Financial Information VirtualScopics (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Acquisitions - ePatch Division of DELTA Danish Electronics, Light, and Acoustics (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Acquisitions - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Intangible Assets and Goodwill - Changes In Carrying Amounts (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 beat-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 8 beat-20160630_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $12,497 and $11,185, at June 30, 2016 and December 31, 2015, respectively Other Receivables, Net, Current Other accounts receivable, net of allowance for doubtful accounts of $291 and $416, at June 30, 2016 and December 31, 2015, respectively Inventory, Net Inventory Total inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Total intangible assets, net Goodwill Balance at the end of the period Balance at the beginning of the period Goodwill Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Capital Lease Obligations, Current Current portion of capital lease obligations Long-term Debt, Current Maturities Current portion of long-term debt Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Deferred Tax Liabilities, Net, Noncurrent Deferred tax liability Capital Lease Obligations, Noncurrent Long-term capital lease obligations Long-term Debt, Excluding Current Maturities Long-term debt Other Liabilities, Noncurrent Other liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock-$.001 par value as of June 30, 2016 and December 31, 2015; 200,000,000 shares authorized as of June 30, 2016 and December 31, 2015; 28,025,489 and 27,277,939 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively Additional Paid in Capital, Common Stock Paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts (in dollars) Allowance for Doubtful Other Receivables, Current Other receivable, allowance for doubtful accounts (in dollars) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Revenues [Abstract] Revenues: Health Care Organization, Revenue Healthcare Sales Revenue, Services, Net Research Technology Services Revenue Technology Revenues Net revenues Revenues Total revenues Cost of Revenue [Abstract] Cost of revenues: Health Care Organization, Expenses, Net Healthcare Cost of Services Research Technology Services Costs Technology Cost of Revenue Total cost of revenues Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: General and Administrative Expense General and administrative Selling and Marketing Expense Sales and marketing Provision for Doubtful Accounts Bad debt expense Research and Development Expense Research and development Other Cost and Expense, Operating Other charges Total Operating Expenses Total operating expenses Operating Income (Loss) Income from operations Nonoperating Income (Expense) Interest and other loss, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income taxes Income before income taxes Income Tax Expense (Benefit) (Provision for) benefit from income taxes Income tax expense (benefit) Net Income (Loss) Available to Common Stockholders, Basic Net income Net income Net income Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation (loss) gain Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Earnings Per Share, Basic and Diluted [Abstract] Net income per share: Earnings Per Share, Basic Basic (in dollars per share) Basic net income per share Earnings Per Share, Diluted Diluted (in dollars per share) Diluted net income per share Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted average shares used in computing basic net income per share Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted average shares used in computing diluted net income per share CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] OPERATING ACTIVITIES Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Depreciation Depreciation Straight Line Rent Non-cash lease expense Deferred Income Tax Expense (Benefit) Deferred income tax expense Share-based Compensation Stock-based compensation Amortization of Intangible Assets Amortization of intangibles Amount of accretion of the debt discount. Accretion Of Debt Discount Accretion of discount on debt Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts and Other Receivables Accounts and other receivables Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities The increase (decrease) during the reporting period in the aggregate amount associated with civil investigative demand. Increase Decrease in Civil Investigative Demand Liability associated with the Civil Investigative Demand Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] INVESTING ACTIVITIES Payments to Acquire Businesses, Net of Cash Acquired Acquisition of business, net of cash acquired Total consideration paid, net of cash acquired Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment and investment in internally developed software Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] FINANCING ACTIVITIES The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises, net of the amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award. Proceeds From Issuance Of Shares Under Incentive And Share-based Compensation Plans, Net Of Payments Related to Tax Withholding For Share-based Compensation Payments related to the exercising of stock options and vesting of RSUs and PSUs Proceeds from Long-term Lines of Credit Borrowings under revolving loans Repayments of Long-term Debt Principal payments on long-term debt Repayments of Long-term Capital Lease Obligations Principal payments on capital lease obligations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used in financing activities Net Cash Provided by (Used in) Continuing Operations Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest Paid, Net Cash paid for interest Income Taxes Paid Cash paid for taxes Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Acquisitions Business Combination Disclosure [Text Block] Acquisitions Inventory Inventory Disclosure [Text Block] Inventory Intangible Assets and Goodwill Goodwill and Intangible Assets. Intangible Assets and Goodwill Credit Agreement Debt Disclosure [Text Block] Credit Agreement Stockholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Stockholders' Equity Other Charges Other Income and Other Expense Disclosure [Text Block] Other Charges Income Taxes Income Tax Disclosure [Text Block] Income Taxes Segment Information Segment Reporting Disclosure [Text Block] Segment Information Earnings Per Share, Policy [Policy Text Block] Net Income Per Share Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Equity Method Investments, Policy [Policy Text Block] Equity Method Investments Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill and Acquired Intangible Assets New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of calculation of basic and diluted net income per share Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Acquisitions Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of total consideration and related allocation for net assets acquired Business Acquisition, Pro Forma Information [Table Text Block] Schedule of unaudited pro forma financial information Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Summary of changes in contingent consideration Schedule of Inventory, Current [Table Text Block] Schedule of inventory Schedule of Goodwill [Table Text Block] Schedule of changes in the carrying amounts of goodwill by segment Tabular disclosure of intangible assets excluding goodwill, which may be broken down by segment or major class. Schedule of Intangible Assets Excluding Goodwill [Table Text Block] Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Summary of estimated amortization expense for the next five years Schedule of Share-based Compensation, Activity [Table Text Block] Summary of stock option and restricted stock units and performance stock units activity Schedule of Other Operating Cost and Expense, by Component [Table Text Block] Summary of expenses related to other charges Schedule of Segment Reporting Information, by Segment [Table Text Block] Summary of financial information concerning the entity's reportable segments Earnings Per Share [Abstract] Net income per common share No definition available. Numerator: No definition available. Denominator: Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Potential dilutive common shares due to dilutive stock option and restricted stock units Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts receivable and allowance for doubtful accounts Long-term Debt, Fair Value Fair value of long-term debt Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Equity Method Investments Equity Method Investment, Ownership Percentage Percentage of ownership acquired Equity Method Investments Equity method investment This item represents disclosure of the amount of capital contributions made to unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. Capital Contributions to Equity Method Investment Capital Contributions Proceeds from Equity Method Investment, Dividends or Distributions Dividends from equity investment Income (Loss) from Equity Method Investments Loss from equity investment Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Segment Information Number of Reportable Segments Number of reportable segments Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Business Acquisition, Share Price Share price (in dollars per share) Business Acquisition, Goodwill, Expected Tax Deductible Amount Amount of goodwill preliminarily expected to be deductible for tax purposes Represents the maximum period for finalizing the accounting for acquisitions from the acquisition date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Finalizing Accounting for Acquisition from Acquisition Date, Maximum Period Maximum period for finalizing accounting for acquisition from acquisition date (in years) Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Summary of total consideration and related allocation of net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Fair value of assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Other accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Inventory Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract] Identifiable intangible assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Total identifiable intangible assets Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Weighted Average Life (Years) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Fair value of liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts payable Amount of accrued liabilities assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities Accrued liabilities Amount of capital lease obligation, due within one year or within the normal operating cycle, if longer assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Capital Lease Obligation Current portion of capital lease obligations Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Current portion of long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Capital Lease Obligation Long-term capital lease obligations Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Long-term debt EX-101.PRE 9 beat-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 10 beat-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Jul. 26, 2016
Document and Entity Information
Entity Registrant Name	BioTelemetry, Inc.
Entity Central Index Key	0001574774
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		28,025,489
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 25,443	$ 18,986
Accounts receivable, net of allowance for doubtful accounts of $12,497 and $11,185, at June 30, 2016 and December 31, 2015, respectively	15,325	15,179
Other accounts receivable, net of allowance for doubtful accounts of $291 and $416, at June 30, 2016 and December 31, 2015, respectively	13,094	8,997
Inventory	3,471	2,378
Prepaid expenses and other current assets	1,668	1,505
Total current assets	59,001	47,045
Property and equipment, net	26,282	25,554
Intangible assets, net	32,232	19,981
Goodwill	37,205	29,831
Other assets	1,470	1,732
Total assets	156,190	124,143
Current liabilities:
Accounts payable	10,610	8,496
Accrued liabilities	12,755	11,230
Current portion of capital lease obligations	269	287
Current portion of long-term debt	1,317	1,250
Deferred revenue	3,609	2,625
Total current liabilities	28,560	23,888
Deferred tax liability	1,278	1,233
Long-term capital lease obligations	157	101
Long-term debt	36,014	21,944
Other liabilities	1,683	1,051
Total liabilities	67,692	48,217
Stockholders' equity:
Common stock-$.001 par value as of June 30, 2016 and December 31, 2015; 200,000,000 shares authorized as of June 30, 2016 and December 31, 2015; 28,025,489 and 27,277,939 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	28	27
Paid-in capital	276,484	272,070
Accumulated other comprehensive loss	(160)	(12)
Accumulated deficit	(187,854)	(196,159)
Total stockholders' equity	88,498	75,926
Total liabilities and stockholders' equity	$ 156,190	$ 124,143

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
CONSOLIDATED BALANCE SHEETS
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 12,497	$ 11,185
Other receivable, allowance for doubtful accounts (in dollars)	$ 291	$ 416
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	28,025,489	27,277,939
Common stock, shares outstanding	28,025,489	27,277,939

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Healthcare	$ 42,165	$ 36,255	$ 83,314	$ 71,236
Research	7,896	5,441	13,289	10,869
Technology	2,619	3,116	4,717	6,142
Total revenues	52,680	44,812	101,320	88,247
Cost of revenues:
Healthcare	13,470	12,808	26,632	25,985
Research	4,447	3,233	7,702	6,186
Technology	1,842	2,038	3,438	4,120
Total cost of revenues	19,759	18,079	37,772	36,291
Gross profit	32,921	26,733	63,548	51,956
Operating expenses:
General and administrative	14,388	12,206	26,724	23,603
Sales and marketing	7,124	6,926	14,669	14,109
Bad debt expense	2,664	2,175	5,302	4,524
Research and development	1,965	1,631	3,751	3,596
Other charges	1,659	1,210	3,447	3,070
Total operating expenses	27,800	24,148	53,893	48,902
Income from operations	5,121	2,585	9,655	3,054
Interest and other loss, net	(633)	(439)	(1,056)	(829)
Income before income taxes	4,488	2,146	8,599	2,225
(Provision for) benefit from income taxes	(153)	25	(294)	(123)
Net income	4,335	2,171	8,305	2,102
Other comprehensive income:
Foreign currency translation (loss) gain	(150)	2	(148)	(9)
Comprehensive income	$ 4,185	$ 2,173	$ 8,157	$ 2,093
Net income per share:
Basic (in dollars per share)	$ 0.16	$ 0.08	$ 0.30	$ 0.08
Diluted (in dollars per share)	$ 0.14	$ 0.08	$ 0.28	$ 0.07
Weighted average number of common shares outstanding:
Basic (in shares)	27,960,776	27,071,839	27,665,800	27,003,273
Diluted (in shares)	30,056,717	28,918,106	29,619,296	28,873,089

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
OPERATING ACTIVITIES
Net income	$ 8,305	$ 2,102
Adjustments to reconcile net income to net cash provided by operating activities:
Bad debt expense	5,302	4,524
Depreciation	5,257	4,074
Non-cash lease expense	27	18
Deferred income tax expense	45	123
Stock-based compensation	2,619	2,182
Amortization of intangibles	1,673	1,885
Accretion of discount on debt	109	99
Changes in operating assets and liabilities:
Accounts and other receivables	(5,866)	(4,015)
Inventory	(786)	(640)
Prepaid expenses and other assets	505	668
Accounts payable	1,789	(1,232)
Accrued and other liabilities	(1,453)	(399)
Liability associated with the Civil Investigative Demand		(6,400)
Net cash provided by (used in) operating activities	17,526	2,989
INVESTING ACTIVITIES
Acquisition of business, net of cash acquired	(17,970)
Purchases of property and equipment and investment in internally developed software	(5,692)	(6,669)
Net cash used in investing activities	(23,662)	(6,669)
FINANCING ACTIVITIES
Payments related to the exercising of stock options and vesting of RSUs and PSUs	(1,089)	(935)
Borrowings under revolving loans	14,500
Principal payments on long-term debt	(635)	(313)
Principal payments on capital lease obligations	(183)	(276)
Net cash used in financing activities	12,593	(1,524)
Net increase (decrease) in cash and cash equivalents	6,457	(5,204)
Cash and cash equivalents - beginning of period	18,986	20,007
Cash and cash equivalents - end of period	25,443	14,803
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	654	359
Cash paid for taxes	$ 132	$ 161

XML 16 R6.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

1.Summary of Significant Accounting Policies

Net Income Per Share

We compute net income per share in accordance with Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by giving effect to all potential dilutive common shares, including stock options and restricted stock units.

The following table presents the calculation of basic net income per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
	(Net income in thousands)
Numerator:
Net income	$	4,335	$	2,171	$	8,305	$	2,102
Denominator:
Weighted average shares used in computing basic net income per share	27,960,776		27,071,839		27,665,800		27,003,273
Potential dilutive common shares due to dilutive stock option and restricted stock units	2,095,941		1,846,267		1,953,496		1,869,816

Weighted average shares used in computing diluted net income per share	30,056,717		28,918,106		29,619,296		28,873,089

Net income per share:
Basic net income per share	$	0.16	$	0.08	$	0.30	$	0.08

Diluted net income per share	$	0.14	$	0.08	$	0.28	$	0.07

Fair Value of Financial Instruments

Equity Method Investments

Goodwill and Acquired Intangible Assets

Goodwill is the excess of the purchase price of an acquired business over the amounts assigned to the assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles — Goodwill and Other (“ASC 350”), goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill. If the carrying value of the reporting units’ goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.

Recent Accounting Pronouncements Not Yet Adopted

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Account Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting. The standard will revise accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. The standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The standard will require lessees to recognize most leases on their balance sheet and makes selected changes to lessor accounting. The standard is effective for annual and interim reporting periods beginning after December 15, 2018. A modified retrospective transition approach is required, with certain practical expedients available. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. The standard will require inventory to be measured at the lower of cost or net realizable value. The guidance will not apply to inventories for which cost is determined using the last-in, first-out method or the retail inventory method. The standard is effective for annual and interim reporting periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which has been updated through several revisions and clarifications since its original issuance. The standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which a company expects to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition. The standard will be effective January 1, 2018 with early adoption permissible beginning January 1, 2017. We are currently evaluating the transition method we will elect and the impact the adoption of this standard will have on our consolidated financial statements.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Acquisitions

6 Months Ended

Jun. 30, 2016

Acquisitions

Acquisitions

2. Acquisitions

VirtualScopics, Inc.

The total consideration and related allocation for VirtualScopics is summarized as follows:

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Cash and cash equivalents	$	849
Other accounts receivable	3,679
Inventory	111
Prepaid expenses and other current assets	396
Property and equipment	524
Other assets	10

Identifiable intangible assets:
Customer relationships	5,100		12
Technology	1,900		10
Backlog	3,100		4

Total identifiable intangible assets	10,100

Total assets acquired	15,669


Fair value of liabilities assumed:
Accounts payable	325
Accrued liabilities	3,074
Current portion of capital lease obligations	59
Current portion of long-term debt	66
Deferred revenue	700
Long-term capital lease obligations	162
Long-term debt	97

Total liabilities assumed	4,483

Total identifiable net assets	11,186
Goodwill	4,633

Net assets acquired	$	15,819

For the period from May 11, 2016 to June 30, 2016, VirtualScopics contributed net revenues of $2,589 and net income of $166 to our consolidated results of operations.

Pro forma financial information for the periods presented is summarized as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Revenue	$	54,762	$	47,832	$	107,258	$	94,081

Net income	$	5,021	$	1,847	$	9,643	$	1,541

Net income per common share:
Basic	$	0.18	$	0.07	$	0.35	$	0.06

Diluted	$	0.17	$	0.06	$	0.33	$	0.05

Weighted average number of common shares outstanding:
Basic	27,960,776		27,071,839		27,665,800		27,003,273

Diluted	30,056,717		28,918,106		29,619,296		28,873,089

ePatch Division of DELTA Danish Electronics, Light, and Acoustics

The amounts below represent our preliminary fair value estimates as of June 30, 2016 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period. The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, as well as the identifiable intangible assets. The Company expects to finalize all accounting for the ePatch acquisition within one year of the acquisition date.

The total consideration and related allocation for the ePatch acquisition is summarized as follows:

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Inventory	$	200
Property and equipment	175

Identifiable intangible assets:
Customer relationships	400		10
Technology	3,000		10
Trade names	100		Indefinite

Total identifiable intangible assets	3,500

Total assets acquired	3,875


Fair value of liabilities assumed:
Accrued liabilities	193

Total liabilities assumed	193

Total identifiable net assets	3,682
Goodwill	2,808

Net assets acquired	$	6,490

Contingent Consideration

The following summarizes the changes in our contingent consideration during the six months ended June 30, 2016:

	Total Contingent Consideration
Balance at December 31, 2015	—
Purchase price contingent consideration	$	605

Balance at June 30, 2016	$	605

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 18 R8.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2016

Inventory

Inventory

3. Inventory

Inventory consists of the following:

	June 30, 2016		December 31, 2015
Raw materials	$	2,850	$	2,115
Finished goods	621		263

Total inventory	$	3,471	$	2,378

XML 19 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

6 Months Ended

Jun. 30, 2016

Intangible Assets and Goodwill

Intangible Assets and Goodwill

4.Intangible Assets and Goodwill

The changes in the carrying amounts of goodwill by segment were as follows:

	Reporting Segment
	Healthcare		Research		Technology			Total
Balance at December 31, 2015	$	14,724	$	11,950	$	3,157		$	29,831
Goodwill acquired during the year	—		4,633		2,808			7,441
Impact of foreign exchange	—		—		(67		)	(67		)

Balance at June 30, 2016	$	14,724	$	16,583	$	5,898		$	37,205

The gross carrying amounts and accumulated amortization of our intangible assets as of June 30, 2016 and December 31, 2015 are as follows:

	Estimated Useful Life (Years)	June 30, 2016			December 31, 2015
Customer relationships	5 - 15	$	16,191		$	10,700
Technology, including internally developed software	3 - 10	18,757			13,522
Signed backlog	1 - 4	6,260			3,160
Unsigned backlog	4	600			600
Covenants not to compete	5 - 7	1,040			1,040

Total intangible assets, gross		42,848			29,022

Customer relationships accumulated amortization		(3,083		)	(2,520		)
Technology accumulated amortization		(5,918		)	(5,422		)
Signed backlog accumulated amortization		(3,051		)	(2,609		)
Unsigned backlog accumulated amortization		(575		)	(500		)
Covenants not to compete accumulated amortization		(587		)	(490		)

Total accumulated amortization		(13,214		)	(11,541		)

Indefinite-lived trade names		2,598			2,500

Total intangible assets, net		$	32,232		$	19,981

The estimated amortization expense for the next five years and thereafter is summarized as follows at June 30, 2016:

Remainder of 2016	$	2,125
2017	4,805
2018	4,319
2019	3,832
2020	3,282
2021	2,764
Thereafter	8,507

Total estimated amortization	$	29,634

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Credit Agreement	6 Months Ended
Credit Agreement	Jun. 30, 2016
Credit Agreement
Credit Agreement	5.Credit Agreement On December 30, 2014, we entered into a Credit Agreement with Healthcare Financial Solutions, LLC (“HFS”), previously The General Electric Capital Corporation, as agent for the lenders (“Lenders”), and as a lender and swingline lender. Pursuant to the Credit Agreement, the Lenders agreed to make loans to us as follows: (i) Term Loans in an amount of $25,000 as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed $10,000 and (ii) Revolving Loans up to $15,000. As of June 30, 2016, $14,500 was drawn on the Revolving Loans. The loan, inclusive of Term Loans and Revolving Loans, is recorded on our consolidated balance sheets as of June 30, 2016 in the amount of $37,178, which is net of a debt discount of $695 related to fees paid to HFS and deferred charges of $65. The loan bears interest at an annual rate of LIBOR plus 4.0%, subject to a LIBOR floor of 1.0%. The outstanding principal of the Term Loan will be paid as follows: (i) beginning April 1, 2015, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $312, plus accrued interest; (ii) beginning January 1, 2018, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $625, plus accrued interest; and (iii) the remaining $16,563 will be paid in full on or before December 30, 2019, or such earlier date upon an acceleration of the Term Loan by the Lenders upon an event of default or termination by us. The loan is secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries, as well as a pledge of 65% of the capital stock of the Company’s foreign subsidiaries. The Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of June 30, 2016, we were in compliance with all covenants.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2016

Stockholders' Equity

Stockholders' Equity

6.Stockholders’ Equity

Stock-Based Compensation

Stock option, RSU and PSU activity is summarized as follows:

	Stock Options				Restricted Stock Units				Performance Stock Units
	Number of Shares		Weighted Average Exercise Price		Number of Shares		Weighted Average Grant Date Fair Value		Number of Shares		Weighted Average Grant Date Fair Value
Stock outstanding as of December 31, 2015	3,420,519		$	6.69	690,936		$	6.85	265,990		$	8.68
Granted	282,270		9.67		177,212		9.87		—		—
Cancelled/forfeited	(19,422	)	8.38		(7,405	)	9.57		—		—
Exercised/vested	(125,650	)	3.37		(271,793	)	2.87		—		—

Stock outstanding as of March 31, 2016	3,557,717		$	7.04	588,950		$	9.57	265,990		$	8.68

Granted	100,000		16.61		47,986		15.44		—		—
Cancelled/forfeited	(7,600	)	9.78		—		—		—		—
Exercised/vested	(57,019	)	4.94		(16,240	)	8.01		(132,998	)	8.68

Stock outstanding as of June 30, 2016	3,593,098		$	7.33	620,696		$	10.06	132,992		$	8.68

Employee Stock Purchase Plan

XML 22 R12.htm IDEA: XBRL DOCUMENT

Other Charges

6 Months Ended

Jun. 30, 2016

Other Charges

Other Charges

7.Other Charges

We account for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and record the expenses in other charges in our consolidated statements of operations and record the related accrual in the accrued liabilities line on our consolidated balance sheets. These costs are primarily disclosed as severance and employee related costs below.

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Legal fees	$	1,242	$	1,171	$	2,611	$	2,799
Professional fees	278		12		446		24
Severance and employee related costs	72		27		323		247
Other costs	67		—		67		—

Total	$	1,659	$	1,210	$	3,447	$	3,070

XML 23 R13.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2016
Income Taxes
Income Taxes	8.Income Taxes The income tax provision for interim periods is determined using an estimated annual effective tax rate adjusted for discrete items, if any, which are taken into account in the quarterly period in which they occur. We review and update our estimated annual effective tax rate each quarter. At June 30, 2016, our estimated annual effective tax rate was 3.81%. Income tax expense of $294 was recorded for the six months ended June 30, 2016, primarily due to Alternative Minimum Tax (“AMT”) levied on current year taxable income, net of allowable AMT net operating loss carryovers. At June 30, 2015, our estimated annual effective tax rate was 6.42%. We recorded a tax provision of $123 for the six months ended June 30, 2015, which includes a discrete charge of $117 related to a deferred tax liability recorded for indefinite-lived intangibles. As of June 30, 2016, in accordance with ASC 740, Income Taxes, we maintained a full valuation allowance against net deferred tax assets, with the exception of the deferred tax liability recorded for indefinite lived intangibles. We will continue to maintain a full valuation allowance until such time we can reasonably estimate the probability of realizing a benefit from the deferred tax assets.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Segment Information

6 Months Ended

Jun. 30, 2016

Segment Information

Segment Information

9.Segment Information

For the three months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2016
Revenues	$	42,165	$	7,896	$	2,619	—			$	52,680
Intersegment revenues	—		—		2,282		$	(2,282	)	—
Income (loss) before income taxes	15,582		387		747		(12,228		)	4,488
Depreciation and amortization	2,500		1,080		142		(58		)	3,664
Capital expenditures	1,626		541		12		—			2,179

	Healthcare		Research			Technology		Corporate and Other			Consolidated
June 30, 2015
Revenues	$	36,255	$	5,441		$	3,116	—			$	44,812
Intersegment revenues	4		—			3,023		$	(3,027	)	—
Income (loss) before income taxes	10,990		(175		)	1,359		(10,028		)	2,146
Depreciation and amortization	1,853		933			91		130			3,007
Capital expenditures	3,182		1,413			2		—			4,597

For the six months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2016
Revenues	$	83,314	$	13,289	$	4,717	—			$	101,320
Intersegment revenues	—		—		5,674		$	(5,674	)	—
Income (loss) before income taxes	29,782		405		1,693		(23,281		)	8,599
Depreciation and amortization	4,981		1,884		192		(127		)	6,930
Capital expenditures	4,316		1,350		26		—			5,692

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2015
Revenues	$	71,236	$	10,869	$	6,142	—			$	88,247
Intersegment revenues	4		—		4,014		$	(4,018	)	—
Income (loss) before income taxes	19,879		202		2,272		(20,128		)	2,225
Depreciation and amortization	3,662		1,841		185		271			5,959
Capital expenditures	4,330		2,269		70		—			6,669

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Net Income Per Share

The following table presents the calculation of basic net income per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
	(Net income in thousands)
Numerator:
Net income	$	4,335	$	2,171	$	8,305	$	2,102
Denominator:
Weighted average shares used in computing basic net income per share	27,960,776		27,071,839		27,665,800		27,003,273
Potential dilutive common shares due to dilutive stock option and restricted stock units	2,095,941		1,846,267		1,953,496		1,869,816

Weighted average shares used in computing diluted net income per share	30,056,717		28,918,106		29,619,296		28,873,089

Net income per share:
Basic net income per share	$	0.16	$	0.08	$	0.30	$	0.08

Diluted net income per share	$	0.14	$	0.08	$	0.28	$	0.07

Fair Value of Financial Instruments

Equity Method Investments

Goodwill and Acquired Intangible Assets

Goodwill is the excess of the purchase price of an acquired business over the amounts assigned to the assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles — Goodwill and Other (“ASC 350”), goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill. If the carrying value of the reporting units’ goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.

Recent Accounting Pronouncements Not Yet Adopted

- Definition

Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Schedule of calculation of basic and diluted net income per share

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
	(Net income in thousands)
Numerator:
Net income	$	4,335	$	2,171	$	8,305	$	2,102
Denominator:
Weighted average shares used in computing basic net income per share	27,960,776		27,071,839		27,665,800		27,003,273
Potential dilutive common shares due to dilutive stock option and restricted stock units	2,095,941		1,846,267		1,953,496		1,869,816

Weighted average shares used in computing diluted net income per share	30,056,717		28,918,106		29,619,296		28,873,089

Net income per share:
Basic net income per share	$	0.16	$	0.08	$	0.30	$	0.08

Diluted net income per share	$	0.14	$	0.08	$	0.28	$	0.07

XML 27 R17.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2016

Acquisitions

Summary of changes in contingent consideration

	Total Contingent Consideration
Balance at December 31, 2015	—
Purchase price contingent consideration	$	605

Balance at June 30, 2016	$	605

VirtualScopics

Acquisitions

Schedule of total consideration and related allocation for net assets acquired

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Cash and cash equivalents	$	849
Other accounts receivable	3,679
Inventory	111
Prepaid expenses and other current assets	396
Property and equipment	524
Other assets	10

Identifiable intangible assets:
Customer relationships	5,100		12
Technology	1,900		10
Backlog	3,100		4

Total identifiable intangible assets	10,100

Total assets acquired	15,669


Fair value of liabilities assumed:
Accounts payable	325
Accrued liabilities	3,074
Current portion of capital lease obligations	59
Current portion of long-term debt	66
Deferred revenue	700
Long-term capital lease obligations	162
Long-term debt	97

Total liabilities assumed	4,483

Total identifiable net assets	11,186
Goodwill	4,633

Net assets acquired	$	15,819

Schedule of unaudited pro forma financial information

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Revenue	$	54,762	$	47,832	$	107,258	$	94,081

Net income	$	5,021	$	1,847	$	9,643	$	1,541

Net income per common share:
Basic	$	0.18	$	0.07	$	0.35	$	0.06

Diluted	$	0.17	$	0.06	$	0.33	$	0.05

Weighted average number of common shares outstanding:
Basic	27,960,776		27,071,839		27,665,800		27,003,273

Diluted	30,056,717		28,918,106		29,619,296		28,873,089

ePatch Division

Acquisitions

Schedule of total consideration and related allocation for net assets acquired

			Weighted
			Average Life
	Amount		(Years)
Fair value of assets acquired:
Inventory	$	200
Property and equipment	175

Identifiable intangible assets:
Customer relationships	400		10
Technology	3,000		10
Trade names	100		Indefinite

Total identifiable intangible assets	3,500

Total assets acquired	3,875


Fair value of liabilities assumed:
Accrued liabilities	193

Total liabilities assumed	193

Total identifiable net assets	3,682
Goodwill	2,808

Net assets acquired	$	6,490

XML 28 R18.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

6 Months Ended

Jun. 30, 2016

Inventory

Schedule of inventory

	June 30, 2016		December 31, 2015
Raw materials	$	2,850	$	2,115
Finished goods	621		263

Total inventory	$	3,471	$	2,378

XML 29 R19.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 30, 2016

Intangible Assets and Goodwill

Schedule of changes in the carrying amounts of goodwill by segment

	Reporting Segment
	Healthcare		Research		Technology			Total
Balance at December 31, 2015	$	14,724	$	11,950	$	3,157		$	29,831
Goodwill acquired during the year	—		4,633		2,808			7,441
Impact of foreign exchange	—		—		(67		)	(67		)

Balance at June 30, 2016	$	14,724	$	16,583	$	5,898		$	37,205

Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets

	Estimated Useful Life (Years)	June 30, 2016			December 31, 2015
Customer relationships	5 - 15	$	16,191		$	10,700
Technology, including internally developed software	3 - 10	18,757			13,522
Signed backlog	1 - 4	6,260			3,160
Unsigned backlog	4	600			600
Covenants not to compete	5 - 7	1,040			1,040

Total intangible assets, gross		42,848			29,022

Customer relationships accumulated amortization		(3,083		)	(2,520		)
Technology accumulated amortization		(5,918		)	(5,422		)
Signed backlog accumulated amortization		(3,051		)	(2,609		)
Unsigned backlog accumulated amortization		(575		)	(500		)
Covenants not to compete accumulated amortization		(587		)	(490		)

Total accumulated amortization		(13,214		)	(11,541		)

Indefinite-lived trade names		2,598			2,500

Total intangible assets, net		$	32,232		$	19,981

Summary of estimated amortization expense for the next five years

The estimated amortization expense for the next five years and thereafter is summarized as follows at June 30, 2016:

Remainder of 2016	$	2,125
2017	4,805
2018	4,319
2019	3,832
2020	3,282
2021	2,764
Thereafter	8,507

Total estimated amortization	$	29,634

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2016

Stockholders' Equity

Summary of stock option and restricted stock units and performance stock units activity

	Stock Options				Restricted Stock Units				Performance Stock Units
	Number of Shares		Weighted Average Exercise Price		Number of Shares		Weighted Average Grant Date Fair Value		Number of Shares		Weighted Average Grant Date Fair Value
Stock outstanding as of December 31, 2015	3,420,519		$	6.69	690,936		$	6.85	265,990		$	8.68
Granted	282,270		9.67		177,212		9.87		—		—
Cancelled/forfeited	(19,422	)	8.38		(7,405	)	9.57		—		—
Exercised/vested	(125,650	)	3.37		(271,793	)	2.87		—		—

Stock outstanding as of March 31, 2016	3,557,717		$	7.04	588,950		$	9.57	265,990		$	8.68

Granted	100,000		16.61		47,986		15.44		—		—
Cancelled/forfeited	(7,600	)	9.78		—		—		—		—
Exercised/vested	(57,019	)	4.94		(16,240	)	8.01		(132,998	)	8.68

Stock outstanding as of June 30, 2016	3,593,098		$	7.33	620,696		$	10.06	132,992		$	8.68

XML 31 R21.htm IDEA: XBRL DOCUMENT

Other Charges (Tables)

6 Months Ended

Jun. 30, 2016

Other Charges

Summary of expenses related to other charges

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Legal fees	$	1,242	$	1,171	$	2,611	$	2,799
Professional fees	278		12		446		24
Severance and employee related costs	72		27		323		247
Other costs	67		—		67		—

Total	$	1,659	$	1,210	$	3,447	$	3,070

XML 32 R22.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

6 Months Ended

Jun. 30, 2016

Segment Information

Summary of financial information concerning the entity's reportable segments

For the three months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2016
Revenues	$	42,165	$	7,896	$	2,619	—			$	52,680
Intersegment revenues	—		—		2,282		$	(2,282	)	—
Income (loss) before income taxes	15,582		387		747		(12,228		)	4,488
Depreciation and amortization	2,500		1,080		142		(58		)	3,664
Capital expenditures	1,626		541		12		—			2,179

	Healthcare		Research			Technology		Corporate and Other			Consolidated
June 30, 2015
Revenues	$	36,255	$	5,441		$	3,116	—			$	44,812
Intersegment revenues	4		—			3,023		$	(3,027	)	—
Income (loss) before income taxes	10,990		(175		)	1,359		(10,028		)	2,146
Depreciation and amortization	1,853		933			91		130			3,007
Capital expenditures	3,182		1,413			2		—			4,597

For the six months ended:

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2016
Revenues	$	83,314	$	13,289	$	4,717	—			$	101,320
Intersegment revenues	—		—		5,674		$	(5,674	)	—
Income (loss) before income taxes	29,782		405		1,693		(23,281		)	8,599
Depreciation and amortization	4,981		1,884		192		(127		)	6,930
Capital expenditures	4,316		1,350		26		—			5,692

	Healthcare		Research		Technology		Corporate and Other			Consolidated
June 30, 2015
Revenues	$	71,236	$	10,869	$	6,142	—			$	88,247
Intersegment revenues	4		—		4,014		$	(4,018	)	—
Income (loss) before income taxes	19,879		202		2,272		(20,128		)	2,225
Depreciation and amortization	3,662		1,841		185		271			5,959
Capital expenditures	4,330		2,269		70		—			6,669

XML 33 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Net Income (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income	$ 4,335	$ 2,171	$ 8,305	$ 2,102
Denominator:
Weighted average shares used in computing basic net income per share	27,960,776	27,071,839	27,665,800	27,003,273
Potential dilutive common shares due to dilutive stock option and restricted stock units	2,095,941	1,846,267	1,953,496	1,869,816
Weighted average shares used in computing diluted net income per share	30,056,717	28,918,106	29,619,296	28,873,089
Net income per share:
Basic net income per share	$ 0.16	$ 0.08	$ 0.30	$ 0.08
Diluted net income per share	$ 0.14	$ 0.08	$ 0.28	$ 0.07

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

XML 34 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) $ in Thousands	Jun. 30, 2016 USD ($)
Summary of Significant Accounting Policies
Fair value of long-term debt	$ 38,091

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Equity Method Investments (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) segment	Dec. 31, 2015 USD ($)
Segment Information
Number of reportable segments \| segment		3
Well Bridge Health, Inc
Equity Method Investments
Percentage of ownership acquired			29.00%
Capital Contributions	$ 0	$ 0
Dividends from equity investment	0	0
Loss from equity investment	93	114
Well Bridge Health, Inc \| Goodwill
Equity Method Investments
Equity method investment			$ 891
Well Bridge Health, Inc \| Other Assets
Equity Method Investments
Equity method investment	$ 985	$ 985

XML 36 R26.htm IDEA: XBRL DOCUMENT

Acquisitions - VirtualScopics, Inc. (Details) - USD ($)			2 Months Ended	3 Months Ended		6 Months Ended
Acquisitions - VirtualScopics, Inc. (Details) - USD ($)	Jun. 30, 2016	May 11, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Acquisitions
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Total consideration paid, net of cash acquired						$ 17,970,000
Fair value of liabilities assumed:
Goodwill	$ 37,205,000		$ 37,205,000	$ 37,205,000		37,205,000		$ 29,831,000
Net revenues				52,680,000	$ 44,812,000	101,320,000	$ 88,247,000
Net income				4,335,000	2,171,000	8,305,000	2,102,000
Research Services
Fair value of liabilities assumed:
Goodwill	16,583,000		16,583,000	16,583,000		16,583,000		$ 11,950,000
Net revenues				7,896,000	$ 5,441,000	13,289,000	$ 10,869,000
VirtualScopics
Acquisitions
Total consideration paid, net of cash acquired		$ 14,970,000
Maximum period for finalizing accounting for acquisition from acquisition date (in years)		1 year
Fair value of assets acquired:
Cash and cash equivalents	849,000		849,000	849,000		849,000
Other accounts receivable	3,679,000		3,679,000	3,679,000		3,679,000
Inventory	111,000		111,000	111,000		111,000
Prepaid expenses and other current assets	396,000		396,000	396,000		396,000
Property and equipment	524,000		524,000	524,000		524,000
Other assets	10,000		10,000	10,000		10,000
Identifiable intangible assets:
Total identifiable intangible assets	10,100,000		10,100,000	10,100,000		10,100,000
Total assets acquired	15,669,000		15,669,000	15,669,000		15,669,000
Fair value of liabilities assumed:
Accounts payable	325,000		325,000	325,000		325,000
Accrued liabilities	3,074,000		3,074,000	3,074,000		3,074,000
Current portion of capital lease obligations	59,000		59,000	59,000		59,000
Current portion of long-term debt	66,000		66,000	66,000		66,000
Deferred revenue	700,000		700,000	700,000		700,000
Long-term capital lease obligations	162,000		162,000	162,000		162,000
Long-term debt	97,000		97,000	97,000		97,000
Total liabilities assumed	4,483,000		4,483,000	4,483,000		4,483,000
Total identifiable net assets	11,186,000		11,186,000	11,186,000		11,186,000
Goodwill	4,633,000		4,633,000	4,633,000		4,633,000
Net assets acquired	15,819,000		15,819,000	15,819,000		15,819,000
Net revenues			2,589,000
Net income			166,000
VirtualScopics \| Customer relationships
Identifiable intangible assets:
Total identifiable intangible assets	$ 5,100,000		5,100,000	5,100,000		5,100,000
Weighted Average Life (Years)	12 years
VirtualScopics \| Technology
Identifiable intangible assets:
Total identifiable intangible assets	$ 1,900,000		1,900,000	1,900,000		1,900,000
Weighted Average Life (Years)	10 years
VirtualScopics \| Backlog
Identifiable intangible assets:
Total identifiable intangible assets	$ 3,100,000		$ 3,100,000	$ 3,100,000		$ 3,100,000
Weighted Average Life (Years)	4 years
VirtualScopics \| Common Stock
Acquisitions
Common stock, par value (in dollars per share)		$ 0.001
Share price (in dollars per share)		4.05
Series A and B Convertible Preferred Stock \| VirtualScopics
Acquisitions
Preferred stock, par value (in dollars per share)		0.001
Share price (in dollars per share)		336.30
Series C-1 Convertible Preferred Stock \| VirtualScopics
Acquisitions
Preferred stock, par value (in dollars per share)		0.001
Share price (in dollars per share)		$ 920.00

XML 37 R27.htm IDEA: XBRL DOCUMENT

Acquisitions - Pro Forma Financial Information VirtualScopics (Details) - VirtualScopics - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Pro Forma Financial Information
Revenue	$ 54,762	$ 47,832	$ 107,258	$ 94,081
Net income	$ 5,021	$ 1,847	$ 9,643	$ 1,541
Net income per common share:
Basic (in dollars per share)	$ 0.18	$ 0.07	$ 0.35	$ 0.06
Diluted (in dollars per share)	$ 0.17	$ 0.06	$ 0.33	$ 0.05
Weighted average number of common shares outstanding:
Basic (in shares)	27,960,776	27,071,839	27,665,800	27,003,273
Diluted (in shares)	30,056,717	28,918,106	29,619,296	28,873,089

XML 38 R28.htm IDEA: XBRL DOCUMENT

Acquisitions - ePatch Division of DELTA Danish Electronics, Light, and Acoustics (Details) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended
	Jun. 30, 2016	Apr. 01, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Fair value of liabilities assumed:
Goodwill	$ 37,205		$ 37,205		$ 37,205		$ 29,831
Net revenues			52,680	$ 44,812	101,320	$ 88,247
Net income			4,335	2,171	8,305	2,102
Technology
Fair value of liabilities assumed:
Goodwill	5,898		5,898		5,898		$ 3,157
Net revenues			2,619	$ 3,116	4,717	$ 6,142
ePatch Division
Acquisitions
Cash consideration		$ 3,000
Consideration in common stock (in shares)		244,519
Consideration in common stock		$ 2,885
Maximum performance based earn out		3,000
Total consideration transferred		$ 6,490
Amount of goodwill preliminarily expected to be deductible for tax purposes	2,808		2,808		2,808
Maximum period for finalizing accounting for acquisition from acquisition date (in years)		1 year
Fair value of assets acquired:
Inventory	200		200		200
Property and equipment	175		175		175
Identifiable intangible assets:
Total identifiable intangible assets	3,500		3,500		3,500
Total assets acquired	3,875		3,875		3,875
Fair value of liabilities assumed:
Accrued liabilities	193		193		193
Total liabilities assumed	193		193		193
Total identifiable net assets	3,682		3,682		3,682
Goodwill	2,808		2,808		2,808
Net assets acquired	6,490		6,490		6,490
ePatch Division \| Customer relationships
Identifiable intangible assets:
Total identifiable intangible assets	$ 400		400		400
Weighted Average Life (Years)	10 years
ePatch Division \| Technology
Identifiable intangible assets:
Total identifiable intangible assets	$ 3,000		3,000		3,000
Weighted Average Life (Years)	10 years
ePatch Division \| Trade Names
Identifiable intangible assets:
Total identifiable intangible assets	$ 100		$ 100		$ 100

XML 39 R29.htm IDEA: XBRL DOCUMENT

Acquisitions - Contingent Consideration (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Apr. 01, 2016
Contingent Consideration
Fair value of contingent consideration	$ 605
Summary of changes in contingent consideration
Purchase price contingent consideration	605
Ending balance	605
ePatch Division
Contingent Consideration
Maximum performance based earn out		$ 3,000
ePatch Division \| Other liabilities
Contingent Consideration
Fair value of contingent consideration	605
Summary of changes in contingent consideration
Ending balance	$ 605

XML 40 R30.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory
Raw materials	$ 2,850	$ 2,115
Finished goods	621	263
Total inventory	$ 3,471	$ 2,378

XML 41 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Changes In Carrying Amounts (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	$ 29,831
Goodwill acquired during the year	7,441
Impact of foreign exchange	(67)
Balance at the end of the period	37,205
VirtualScopics
Changes in the carrying amounts of goodwill by segment
Balance at the end of the period	4,633
ePatch Division
Changes in the carrying amounts of goodwill by segment
Balance at the end of the period	2,808
Healthcare
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	14,724
Balance at the end of the period	14,724
Research Services
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	11,950
Balance at the end of the period	16,583
Research Services \| VirtualScopics
Changes in the carrying amounts of goodwill by segment
Goodwill acquired during the year	4,633
Technology
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	3,157
Impact of foreign exchange	(67)
Balance at the end of the period	5,898
Technology \| ePatch Division
Changes in the carrying amounts of goodwill by segment
Goodwill acquired during the year	$ 2,808

XML 42 R32.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Gross Carrying Amounts and Accumulated Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Intangible assets
Total intangible assets, gross	$ 42,848		$ 42,848		$ 29,022
Total accumulated amortization	(13,214)		(13,214)		(11,541)
Total intangible assets, net	32,232		32,232		19,981
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2016	2,125		2,125
2017	4,805		4,805
2018	4,319		4,319
2019	3,832		3,832
2020	3,282		3,282
2021	2,764		2,764
Thereafter	8,507		8,507
Total estimated amortization	29,634		29,634
Amortization of Intangible Assets	994	$ 985	1,673	$ 1,885
Trade Names
Intangible assets
Indefinite-lived trade names	2,598		2,598		2,500
Customer relationships
Intangible assets
Total intangible assets, gross	16,191		16,191		10,700
Total accumulated amortization	(3,083)		$ (3,083)		(2,520)
Customer relationships \| Minimum
Intangible assets
Estimated Useful Life (Years)			5 years
Customer relationships \| Maximum
Intangible assets
Estimated Useful Life (Years)			15 years
Technology, including internally developed software
Intangible assets
Total intangible assets, gross	18,757		$ 18,757		13,522
Total accumulated amortization	(5,918)		$ (5,918)		(5,422)
Technology, including internally developed software \| Minimum
Intangible assets
Estimated Useful Life (Years)			3 years
Technology, including internally developed software \| Maximum
Intangible assets
Estimated Useful Life (Years)			10 years
Signed backlog
Intangible assets
Total intangible assets, gross	6,260		$ 6,260		3,160
Total accumulated amortization	(3,051)		$ (3,051)		(2,609)
Signed backlog \| Minimum
Intangible assets
Estimated Useful Life (Years)			1 year
Signed backlog \| Maximum
Intangible assets
Estimated Useful Life (Years)			4 years
Unsigned backlog
Intangible assets
Estimated Useful Life (Years)			4 years
Total intangible assets, gross	600		$ 600		600
Total accumulated amortization	(575)		(575)		(500)
Covenants not to compete
Intangible assets
Total intangible assets, gross	1,040		1,040		1,040
Total accumulated amortization	$ (587)		$ (587)		$ (490)
Covenants not to compete \| Minimum
Intangible assets
Estimated Useful Life (Years)			5 years
Covenants not to compete \| Maximum
Intangible assets
Estimated Useful Life (Years)			7 years

XML 43 R33.htm IDEA: XBRL DOCUMENT

Credit Agreement (Details) - USD ($) $ in Thousands		6 Months Ended
Credit Agreement (Details) - USD ($) $ in Thousands	Dec. 30, 2014	Jun. 30, 2016
HSF \| Term Loan
Credit Agreement
Maximum borrowing capacity	$ 25,000
Additional uncommitted borrowing capacity	10,000
HSF \| Revolving Loan
Credit Agreement
Maximum borrowing capacity	15,000
Amount drawn on credit borrowing		$ 14,500
HSF \| Term Loans and Revolving Loans
Credit Agreement
Loan balance net of original issue discount		37,178
Original issue discount		695
Deferred Long-term Liability Charges		$ 65
GE Capital
Credit Agreement
Percentage of capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium pledged to secure loan		65.00%
GE Capital \| LIBOR
Credit Agreement
Debt instrument, basis spread on variable rate (as a percent)		4.00%
LIBOR floor (as a percent)		1.00%
GE Capital \| Term Loan \| April 2015 to December 2017
Credit Agreement
Principal amount of quarterly installment payments	312
GE Capital \| Term Loan \| January 2018 to September 2019
Credit Agreement
Principal amount of quarterly installment payments	625
GE Capital \| Term Loan \| October 2019 to December 2019
Credit Agreement
Principal amount of quarterly installment payments	$ 16,563

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Jan. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Stock-Based Compensation
Stock based compensation		$ 1,441		$ 1,062	$ 2,619	$ 2,182
Stock options
Number of Shares
Balance at the beginning of the period (in shares)	3,420,519	3,557,717	3,420,519		3,420,519
Granted (in shares)		100,000	282,270
Cancelled/forfeited (in shares)		(7,600)	(19,422)
Exercised (in shares)		(57,019)	(125,650)
Balance at the end of the period (in shares)		3,593,098	3,557,717		3,593,098		3,420,519
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 6.69	$ 7.04	$ 6.69		$ 6.69
Granted (in dollars per share)		16.61	9.67
Cancelled (in dollars per share)		9.78	8.38
Exercised (in dollars per share)		4.94	3.37
Balance at the end of the period (in dollars per share)		$ 7.33	$ 7.04		$ 7.33		$ 6.69
RSUs
Number of Shares
Balance at the beginning of the period (in shares)	690,936	588,950	690,936		690,936
Granted (in shares)		47,986	177,212
Forfeited (in shares)			(7,405)
Vested (in shares)		(16,240)	(271,793)
Balance at the end of the period (in shares)		620,696	588,950		620,696		690,936
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)	$ 6.85	$ 9.57	$ 6.85		$ 6.85
Granted (in dollars per share)		15.44	9.87
Forfeited (in dollars per share)			9.57
Vested (in dollars per share)		8.01	2.87
Balance at the end of the period (in dollars per shares)		$ 10.06	$ 9.57		$ 10.06		$ 6.85
PSUs
Stock-Based Compensation
Stock based compensation			$ 355	$ 0	$ 444	$ 0
Number of Shares
Balance at the beginning of the period (in shares)	265,990	265,990	265,990		265,990
Vested (in shares)		(132,998)
Balance at the end of the period (in shares)		132,992	265,990		132,992		265,990
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)	$ 8.68	$ 8.68	$ 8.68		$ 8.68
Vested (in dollars per share)		8.68
Balance at the end of the period (in dollars per shares)		$ 8.68	$ 8.68		$ 8.68		$ 8.68
PSOs
Stock-Based Compensation
Stock based compensation					$ 0
Number of Shares
Granted (in shares)							200,000
Number of Shares
Forfeited (in shares)		0			0
Vested (in shares)		0			0
2008 Option Plan
Stock-Based Compensation
Common stock available for grant (in shares)		2,746,978			2,746,978
2008 Option Plan \| Stock options
Stock-Based Compensation
Increase in the number of options available to be granted (in shares)	1,091,118

XML 45 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jan. 31, 2016	Jun. 30, 2016	Jun. 30, 2016
Employee stock purchase plan
Common stock purchased (in shares)		77,844
Net proceeds from the issuance of shares of common stock (in dollars)			$ 531
Increase in number of shares available for grant	272,779
Number of remaining shares available for purchase		698,220	698,220

XML 46 R36.htm IDEA: XBRL DOCUMENT

Other Charges (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Other Charges (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Charges
Legal fees	$ 1,242	$ 1,171	$ 2,611	$ 2,799
Professional fees	278	12	446	24
Severance and employee related costs	72	27	323	247
Other costs	67		67
Total	$ 1,659	$ 1,210	$ 3,447	$ 3,070

XML 47 R37.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Taxes
Estimated annual effective tax rate (as a percent)	3.81%	6.42%
Income tax expense (benefit)	$ 153	$ (25)	$ 294	$ 123
Mednet
Income Taxes
Income tax expense (benefit)				(123)
State income tax expense (benefit)				$ 117

XML 48 R38.htm IDEA: XBRL DOCUMENT

Segment Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
Segment Information (Details) $ in Thousands	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) item	Jun. 30, 2015 USD ($)
Segment information
Number of operating segments \| item			3
Revenues	$ 52,680	$ 44,812	$ 101,320	$ 88,247
Income (loss) before income taxes	4,488	2,146	8,599	2,225
Depreciation and amortization	3,664	3,007	6,930	5,959
Capital expenditures	2,179	4,597	5,692	6,669
Healthcare
Segment information
Revenues	42,165	36,255	83,314	71,236
Capital expenditures	1,626	3,182	4,316	4,330
Research Services
Segment information
Revenues	7,896	5,441	13,289	10,869
Capital expenditures	541	1,413	1,350	2,269
Technology
Segment information
Revenues	2,619	3,116	4,717	6,142
Capital expenditures	12	2	26	70
Operating segments \| Healthcare
Segment information
Revenues		4		4
Income (loss) before income taxes	15,582	10,990	29,782	19,879
Depreciation and amortization	2,500	1,853	4,981	3,662
Operating segments \| Research Services
Segment information
Income (loss) before income taxes	387	(175)	405	202
Depreciation and amortization	1,080	933	1,884	1,841
Operating segments \| Technology
Segment information
Revenues	2,282	3,023	5,674	4,014
Income (loss) before income taxes	747	1,359	1,693	2,272
Depreciation and amortization	142	91	192	185
Corporate and Other
Segment information
Revenues	(2,282)	(3,027)	(5,674)	(4,018)
Income (loss) before income taxes	(12,228)	(10,028)	(23,281)	(20,128)
Depreciation and amortization	$ (58)	$ 130	$ (127)	$ 271

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 134 221 1 false 41 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.cardionet.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.cardionet.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.cardionet.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.cardionet.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.cardionet.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 10101 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 6 false false R7.htm 10201 - Disclosure - Acquisitions Sheet http://www.cardionet.com/role/DisclosureAcquisitions Acquisitions Notes 7 false false R8.htm 10301 - Disclosure - Inventory Sheet http://www.cardionet.com/role/DisclosureInventory Inventory Notes 8 false false R9.htm 10401 - Disclosure - Intangible Assets and Goodwill Sheet http://www.cardionet.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 9 false false R10.htm 10501 - Disclosure - Credit Agreement Sheet http://www.cardionet.com/role/DisclosureCreditAgreement Credit Agreement Notes 10 false false R11.htm 10601 - Disclosure - Stockholders' Equity Sheet http://www.cardionet.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 10701 - Disclosure - Other Charges Sheet http://www.cardionet.com/role/DisclosureOtherCharges Other Charges Notes 12 false false R13.htm 10801 - Disclosure - Income Taxes Sheet http://www.cardionet.com/role/DisclosureIncomeTaxes Income Taxes Notes 13 false false R14.htm 10901 - Disclosure - Segment Information Sheet http://www.cardionet.com/role/DisclosureSegmentInformation Segment Information Notes 14 false false R15.htm 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30103 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 30203 - Disclosure - Acquisitions (Tables) Sheet http://www.cardionet.com/role/DisclosureAcquisitionsTables Acquisitions (Tables) Tables http://www.cardionet.com/role/DisclosureAcquisitions 17 false false R18.htm 30303 - Disclosure - Inventory (Tables) Sheet http://www.cardionet.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.cardionet.com/role/DisclosureInventory 18 false false R19.htm 30403 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.cardionet.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.cardionet.com/role/DisclosureIntangibleAssetsAndGoodwill 19 false false R20.htm 30603 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.cardionet.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.cardionet.com/role/DisclosureStockholdersEquity 20 false false R21.htm 30703 - Disclosure - Other Charges (Tables) Sheet http://www.cardionet.com/role/DisclosureOtherChargesTables Other Charges (Tables) Tables http://www.cardionet.com/role/DisclosureOtherCharges 21 false false R22.htm 30903 - Disclosure - Segment Information (Tables) Sheet http://www.cardionet.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.cardionet.com/role/DisclosureSegmentInformation 22 false false R23.htm 40101 - Disclosure - Summary of Significant Accounting Policies - Net Income (Loss) (Details) Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossDetails Summary of Significant Accounting Policies - Net Income (Loss) (Details) Details 23 false false R24.htm 40102 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Details 24 false false R25.htm 40103 - Disclosure - Summary of Significant Accounting Policies - Equity Method Investments (Details) Sheet http://www.cardionet.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityMethodInvestmentsDetails Summary of Significant Accounting Policies - Equity Method Investments (Details) Details 25 false false R26.htm 40201 - Disclosure - Acquisitions - VirtualScopics, Inc. (Details) Sheet http://www.cardionet.com/role/DisclosureAcquisitionsVirtualscopicsIncDetails Acquisitions - VirtualScopics, Inc. (Details) Details 26 false false R27.htm 40202 - Disclosure - Acquisitions - Pro Forma Financial Information VirtualScopics (Details) Sheet http://www.cardionet.com/role/DisclosureAcquisitionsProFormaFinancialInformationVirtualscopicsDetails Acquisitions - Pro Forma Financial Information VirtualScopics (Details) Details 27 false false R28.htm 40203 - Disclosure - Acquisitions - ePatch Division of DELTA Danish Electronics, Light, and Acoustics (Details) Sheet http://www.cardionet.com/role/DisclosureAcquisitionsEpatchDivisionOfDeltaDanishElectronicsLightAndAcousticsDetails Acquisitions - ePatch Division of DELTA Danish Electronics, Light, and Acoustics (Details) Details 28 false false R29.htm 40204 - Disclosure - Acquisitions - Contingent Consideration (Details) Sheet http://www.cardionet.com/role/DisclosureAcquisitionsContingentConsiderationDetails Acquisitions - Contingent Consideration (Details) Details 29 false false R30.htm 40301 - Disclosure - Inventory (Details) Sheet http://www.cardionet.com/role/DisclosureInventoryDetails Inventory (Details) Details http://www.cardionet.com/role/DisclosureInventoryTables 30 false false R31.htm 40401 - Disclosure - Intangible Assets and Goodwill - Changes In Carrying Amounts (Details) Sheet http://www.cardionet.com/role/DisclosureIntangibleAssetsAndGoodwillChangesInCarryingAmountsDetails Intangible Assets and Goodwill - Changes In Carrying Amounts (Details) Details 31 false false R32.htm 40402 - Disclosure - Intangible Assets and Goodwill - Gross Carrying Amounts and Accumulated Amortization (Details) Sheet http://www.cardionet.com/role/DisclosureIntangibleAssetsAndGoodwillGrossCarryingAmountsAndAccumulatedAmortizationDetails Intangible Assets and Goodwill - Gross Carrying Amounts and Accumulated Amortization (Details) Details 32 false false R33.htm 40501 - Disclosure - Credit Agreement (Details) Sheet http://www.cardionet.com/role/DisclosureCreditAgreementDetails Credit Agreement (Details) Details http://www.cardionet.com/role/DisclosureCreditAgreement 33 false false R34.htm 40601 - Disclosure - Stockholders' Equity (Details) Sheet http://www.cardionet.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.cardionet.com/role/DisclosureStockholdersEquityTables 34 false false R35.htm 40602 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) Sheet http://www.cardionet.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails Stockholders' Equity - Employee Stock Purchase Plan (Details) Details 35 false false R36.htm 40701 - Disclosure - Other Charges (Details) Sheet http://www.cardionet.com/role/DisclosureOtherChargesDetails Other Charges (Details) Details http://www.cardionet.com/role/DisclosureOtherChargesTables 36 false false R37.htm 40801 - Disclosure - Income Taxes (Details) Sheet http://www.cardionet.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.cardionet.com/role/DisclosureIncomeTaxes 37 false false R38.htm 40901 - Disclosure - Segment Information (Details) Sheet http://www.cardionet.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.cardionet.com/role/DisclosureSegmentInformationTables 38 false false All Reports Book All Reports beat-20160630.xml beat-20160630.xsd beat-20160630_cal.xml beat-20160630_def.xml beat-20160630_lab.xml beat-20160630_pre.xml true true ZIP 55 0001104659-16-136568-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-16-136568-xbrl.zip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›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